


# Selective Neutral pH Inhibitor of Cathepsin B Designed Based on Cleavage Preferences at Cytosolic and Lysosomal pH Conditions

Michael C. Yoon, Angelo Solania, Zhenze Jiang, Mitchell P. Christy, Sonia Podvin, Charles Mosier, Christopher B. Lietz, Gen Ito, William H. Gerwick, Dennis W. Wolan, Gregory Hook, Anthony J. O'Donoghue,\* and Vivian Hook\*



Isosomes for protein degradation, but in numerous human diseases, cathepsin B translocates to the cytosol having neutral pH where the enzyme activates inflammation and cell death. Cathepsin B is active at both the neutral pH 7.2 of the cytosol and the acidic pH 4.6 within lysosomes. We evaluated the hypothesis that cathepsin B may possess pH-dependent cleavage preferences that can be utilized for design of a selective neutral pH inhibitor by (1) analysis of differential cathepsin B cleavage profiles at neutral pH compared to acidic pH using multiplex substrate profiling by mass spectrometry (MSP-MS), (2) design of pH-selective peptide–7amino-4-methylcoumarin (AMC) substrates, and (3) design and validation of Z-Arg-Lysacyloxymethyl ketone (AOMK) as a selective neutral pH inhibitor. Cathepsin B displayed preferences for cleaving peptides with Arg in the P2 position at pH 7.2 and Glu in the P2 position at pH 4.6, represented by its primary dipeptidyl carboxypeptidase and modest endopeptidase activity. These properties led to design of the substrate Z-Arg-Lys-AMC having



neutral pH selectivity, and its modification with the AOMK warhead to result in the inhibitor Z-Arg-Lys–AOMK. This irreversible inhibitor displays nanomolar potency with 100-fold selectivity for inhibition of cathepsin B at pH 7.2 compared to pH 4.6, shows specificity for cathepsin B over other cysteine cathepsins, and is cell permeable and inhibits intracellular cathepsin B. These findings demonstrate that cathepsin B possesses pH-dependent cleavage properties that can lead to development of a potent, neutral pH inhibitor of this enzyme.

# INTRODUCTION

Cathepsin B functions in lysosomes for protein degradation and maintenance of cellular homeostasis.<sup>1–3</sup> Cathepsin B is a member of the family of cysteine cathepsin proteases that participate in lysosomal protein degradation, together with aspartyl and serine cathepsins.<sup>4,5</sup> Cathepsin B normally functions within the acidic pH 4.6 environment in lysosomes.<sup>6–8</sup> However, significant cathepsin B activity occurs at the neutral pH 7.2 of the cytosol and other cellular compartments as well as extracellular locations.<sup>9–11</sup>

Evidence for neutral pH locations of cathepsin B functions<sup>12–15</sup> suggests the hypothesis that differential cleavage properties of this enzyme at neutral compared to acidic pH conditions may provide the basis for design and development of a neutral pH-selective inhibitor, which represents the purpose of this study. In numerous disease conditions, cathepsin B functions in the cytosol at neutral pH, rather than in lysosomes. Lysosomal leakage of cathepsin B to the neutral cytosol occurs in numerous brain disorders, including Alzheimer's disease,<sup>12–17</sup> traumatic brain injury (TBI),<sup>12,18,19</sup> and neurodegenerative conditions,<sup>26–32</sup> Cytosolic cathepsin B initiates apoptotic cell death<sup>33–36</sup> and activates inflammatory


IL-1 $\beta$  production.<sup>31,37–39</sup> Cathepsin B participates in behavioral deficits, demonstrated by cathepsin B gene knockout and inhibitor studies in animal models of TBI, AD, ischemia, and related disorders.<sup>12,40,41</sup> This enzyme also functions at the neutral pH of the extracellular environment in cancer<sup>42–46</sup> and rheumatoid arthritis,<sup>47</sup> as well as at other neutral pH locations including nuclei.<sup>48–50</sup> The prevalence of cathepsin B functions at neutral pH locations emphasizes the critical importance of this study to gain an understanding of its neutral pH properties compared to its normal acidic lysosomal features.

Cathepsin B is active at the neutral pH  $7.2^{9,10}$  of the cytosol, <sup>51,52</sup> as well as at the acidic pH  $4.6^{6-8}$  within lysosomes.<sup>4</sup> The 400-fold difference in proton concentration at pH 4.6 compared to pH 7.2 alters the charge state of cathepsin B<sup>12</sup> and its substrates. These distinct pH conditions lead to the hypothesis that cathepsin B may possess different


Received: February 24, 2021 Accepted: July 29, 2021



#### pubs.acs.org/acschemicalbiology



**Figure 1.** Workflow to analyze cathepsin B substrate cleavage site preferences for design of pH-selective inhibitors. (a) Cathepsin B substrate cleavage properties assessed at pH 7.2 and pH 4.6 by multiplex substrate profiling by mass spectrometry (MSP-MS) analyses. The substrate cleavage profiles of cathepsin B at pH 7.2 and pH 4.6 were assessed by MSP-MS analyses. Cathepsin B was incubated (at RT, for 15 and 60 min) at pH 7.2 and pH 4.6 were identified and quantitated by LC-MS/MS analyses. The frequencies of amino acid residues at the P2 to P2' positions of the P1– $\downarrow$ P1' cleavage sites were assessed. (b) Design of pH-selective peptide–AMC substrates. Substrates representing the preferred residues at P1 and P2 positions at pH 7.2 and pH 4.6 were utilized for development of pH-selective peptide–AMC substrates of cathepsin B. These substrates contained a C-terminal 7-amino-4-methylcoumarin (AMC) reporter group and an N-terminal carboxybenzyl (Z) group. (c) Design of pH-selective peptide–AOMK inhibitors were synthesized based on the AMC substrates that have high selectivity for cleavage at either pH 7.2 or pH 4.6.



**Figure 2.** Cathepsin B activity at pH 7.2 and pH 4.6. Cathepsin B was preincubated at pH 7.2 or pH 4.6 at RT (27 °C) or at 37 °C for 30 min to 4 h. Z-Phe-Arg–AMC substrate (40  $\mu$ M) was then added and proteolytic activity was monitored by measurement of AMC fluorescence. Activity is expressed relative to control cathepsin B with no preincubation (100%); data are displayed as the mean ± SEM (*n* = 4).


substrate cleavage preferences at cytosolic neutral pH compared to lysosomal acidic pH. We tested this hypothesis by comparing the substrate cleavage properties of cathepsin B at both pH conditions by global multiplex substrate profiling by mass spectrometry (MSP-MS) using a peptide substrate library consisting of 228 peptides designed to contain diverse protease cleavage sites.<sup>53,54</sup> Furthermore, MSP-MS directly assesses the location of each cleavage site and can, therefore, distinguish aminopeptidase,<sup>55,56</sup> endopeptidase,<sup>57,58</sup> and carboxypeptidase activities.<sup>53,59</sup> Results showed that cathepsin B displays pH-selective cleavage properties represented by its prominent dipeptidyl carboxypeptidase activity and modest endopeptidase activity.

Based on the distinct cathepsin B cleavage properties at neutral pH compared to acidic pH conditions, peptide-AMC substrates and novel peptidic-AOMK inhibitors of cathepsin B were designed and evaluated for pH selectivity. Notably, Z-Arg-Lys-AOMK was revealed as a potent and selective inhibitor of neutral pH 7.2 cathepsin B activity. This inhibitor displayed high specificity for cathepsin B compared to other lysosomal cysteine cathepsins. These results demonstrate that the unique pH-dependent cleavage properties of cathepsin B provide the basis for design of Z-Arg-Lys-AOMK as a neutral pH inhibitor of cathepsin B. These findings suggest that neutral pH cathepsin B represents a unique form of the enzyme compared to the normal lysosomal cathepsin B.


# RESULTS AND DISCUSSION

**Results.** Strategy to Assess Cleavage Properties of Cathepsin B for Design of a Neutral pH-Selective Inhibitor. The workflow used to analyze cathepsin B cleavage properties for development of a neutral pH inhibitor is illustrated in Figure 1. Unbiased MSP-MS assays evaluated the cleavage properties of cathepsin B at neutral pH 7.2 and acidic pH 4.6 using a peptide library consisting of 228 peptide substrates (14 residues in length) containing 2964 diverse cleavage sites.

В



**Figure 3.** Cathepsin B peptide cleavage analyses illustrate major dipeptidyl carboxypeptidase activity at pH 7.2 and pH 4.6, demonstrated by MSP-MS. (a) Cleavage at peptide bonds no. 1-13 of 14-mer peptide library substrates by cathepsin B. Cathepsin B cleavage of the 228 14-mer peptide library at pH 7.2 and pH 4.6 was evaluated as the number of cleavages occurring at each of the peptide bonds no. 1-13, that were generated at pH 7.2 and pH 4.6. (b) Time-dependent cleavage at position 10 of peptide substrates at pH 7.2 and pH 4.6. The number of cleavages by cathepsin B at peptide bond no. 10 at 15 and 60 min incubation is shown. The time-dependent increase in the number of cleavages at position no. 10 may be consistent with sequential dipeptidyl carboxypeptidase cleavages.




**Figure 4.** Differential cathepsin B substrate cleavage preferences at neutral pH 7.2 compared to acidic pH 4.6. (a) pH-dependent cleavage preferences of cathepsin B at pH 7.2 illustrated by IceLogo. IceLogo analysis demonstrates the relative frequency of amino acids at the P2, P1, P1', and P2' positions that surround the cleavage site (purple arrow). Residues shown in gray were not found at the indicated position. The amino acid described with lowercase "n" corresponds to norleucine, a sulfur-free isostere of methionine. Residues colored in red or blue were used in design of selective dipeptide–AMC substrates for pH 7.2 and pH 4.6, respectively. (b) pH-dependent cleavage preferences at pH 4.6 illustrated by IceLogo. IceLogo shows the preferred residues for the P2 to P2' positions for cleavages occurring at pH 4.6. IceLogo features are described in the panel a description. (c) Dipeptide–AMC substrates selective for cathepsin B activity at pH 7.2 or pH 4.6. Based on MSP-MS peptide cleavage data for the preferred P2 and P1 residues adjacent to cleavage sites, peptide–AMC substrates selective for pH 7.2 and for pH 4.6 were designed and synthesized. Cathepsin B specific activities with each of the peptide–AMC substrates (40  $\mu$ M final concentration) were assessed at pH 7.2 (red bars) and pH 4.6 (blue bars). (d) Ratios of cathepsin B specific activities at pH 7.2 and pH 4.6. The ratios of cathepsin B specific activity for pH 7.2/pH 4.6 and for pH 4.6/pH 7.2 are shown. Peptide–AMC substrates with a high ratio of pH 7.2/pH 4.6, and high ratio of pH 4.6/pH 7.2, were selected for modification by AOMK for inhibitor development.

Cathepsin B cleavage products were identified and quantified by nano-liquid chromatography tandem mass spectrometry (nano-LC-MS/MS) to determine the frequencies of amino acid residues adjacent to cleavage sites at P1- $\downarrow$ P1' residues. Preferred residues at the P2 and P1 positions were utilized for design of dipeptide fluorogenic substrates. Substrate sequences that were selectively hydrolyzed by cathepsin B at pH 7.2 or 4.6 were synthesized with the acyloxymethyl ketone (AOMK) warhead to generate peptidic inhibitors.

*Cathepsin B Stability at Neutral pH 7.2 and Acidic pH 4.6.* Prior to determining the substrate cleavage profiles of cathepsin B, we evaluated enzyme stability at pH 7.2 and pH 4.6 by preincubating the enzyme for up to 4 h at RT (RT, 27 °C) and at 37 °C, followed by assays with Z-Phe-Arg–AMC substrate. After 1 h of preincubation, the relative activity at each pH and temperature was above 50% and decreased with longer preincubation times (Figure 2). We, therefore, performed the MSP-MS cleavage assays at RT for up to 1 h to generate data for active enzyme. These *in vitro* assays show that cathepsin B is active at both pH 7.2 and pH 4.6 and represent a model for studying cathepsin B activity.

Substrate Cleavage Profiling of Cathepsin B Demonstrates Strong Dipeptidyl Carboxypeptidase Specificity. Human recombinant cathepsin B was incubated with the 228 14-mer library for 60 min followed by nano-LC-MS/MS and PEAKS bioinformatics to quantify peptide products. At pH 7.2, cathepsin B cleaved 66 peptide bond sites, and at pH 4.6, the enzyme cleaved 142 sites (Figure S1). Cleavage was defined by peptide products having intensity values that were at least 8fold above that in the denatured enzyme control, based on the



**Figure 5.** Dipeptide–AMC substrates that selectively monitor cathepsin B activity at neutral pH 7.2 compared to acidic pH 4.6, illustrated by  $k_{cat}/K_m$  values. (a) Z-Arg-Lys–AMC, pH 7.2 selective substrate. Cathepsin B activity with Z-Arg-Lys–AMC substrate at pH 7.2 and pH 4.6 was evaluated over a concentration range of 2.6  $\mu$ M to 225  $\mu$ M. (b) Z-Glu-Lys–AMC, pH 4.6 selective substrate. Cathepsin B activity was assessed with Z-Glu-Lys–AMC substrate at pH 7.2 and pH 4.6. (c) Z-Phe-Arg–AMC, substrate for both pH 7.2 and pH 4.6. Cathepsin B activity with Z-Phe-Arg–AMC substrate, a commonly used substrate, <sup>77–79</sup> at pH 7.2 and pH 4.6.

criteria to minimize false positive rate (Figure S2). The distribution of cleavages at each of the 13 peptide bonds among the peptide substrates was quantified, and proteolysis was found to occur primarily at position no. 12 indicating dipeptidyl carboxypeptidase activity (Figure 3a). Cleavage at position no. 10 was also prevalent. Fewer numbers of cleavages occurred at position nos. 7–9 and 11, which may represent endopeptidase cleavages, and no cleavages were observed at position nos. 1–6.

The presence of prominent dipeptidyl carboxypeptidase activity suggested that sequential cleavage at position 12 followed by cleavage at position 10 may occur in a time-dependent manner. Evaluation of the number of cleavages occurring at position 10 at 15 and 60 min found that increases occurred in a time-dependent manner (Figure 3b), consistent with dipeptidyl carboxypeptidase processing at position 12 followed by such cleavages at position 10 (Table S1). These findings illustrate the primary exopeptidase activity of cathepsin B as a dipeptidyl carboxypeptidase, with low endopeptidase activity, in both neutral and acidic pH conditions.

*pH-Dependent Cleavage Properties of Cathepsin B.* Cathepsin B displayed differences in cleavage preferences at pH 7.2 compared to pH 4.6. The frequencies of amino acid residues located at positions P2-P1- $\downarrow$ P1'-P2' to generate cleaved peptide products were analyzed by MSP-MS for the major cleavages occurring as dipeptidyl carboxypeptidase cleavages at position 12. IceLogo schematically illustrates the relative frequency of amino acid residues occurring at P2-P1- $\downarrow$ P1'-P2' residues at pH 7.2 and 4.6 (Figure 4a,b).

At the P1 position, cathepsin B at pH 7.2 preferred the basic residues Arg and Lys, along with norleucine and Tyr (Figure 4a). At pH 4.6, the P1 positions displayed preferences for the noncharged Thr and Gly residues, as well as the basic residue Arg (Figure 4b).

At the P2 position, differences in the preferences for negative and positive residues were observed at pH 7.2 and pH 4.6 (Figure 4a,b). At pH 4.6, the acidic Glu residue was a preferred residue at the P2 position, as well as hydrophobic Val. In contrast, at pH 7.2, the basic residues Arg, Lys, and His were preferred at the P2 position, as well as Trp. These preferred P2 residues appear consistent with the presence of Glu245 in the S2 pocket of the protease that interacts with the P2 residue of the cathepsin B substrate.<sup>60</sup> At pH 4.6, the


uncharged Glu245 could interact with the uncharged Glu as the P2 residue, while at neutral pH 7.2, the negatively charged Glu245 would be amenable to interacting with the positively charged P2 basic Arg or Lys residues. These preferred residues at the P2 positions may be informative for design of pHselective substrates of cathepsin B.

Development of pH-Selective Peptide-AMC Substrates for Cathepsin B. The MSP-MS substrate profiling results provided the basis for design of pH-selective dipeptide-AMC substrates (Figure 4c). A series of pH 7.2 selective substrates were designed with basic residues at the P2 position, consisting of Z-Arg-Lys-AMC, Z-Lys-Lys-AMC, Z-Lys-Arg-AMC, and Z-Arg-Arg-AMC. At pH 4.6, the preference for Glu at the P2 position was used for design of the pH 4.6 selective substrates Z-Glu-Lys-AMC and Z-Glu-Arg-AMC.

Evaluation of pH substrate selectivity found that dipeptide substrates with basic residues at both P2 and P1 positions were more rapidly cleaved at neutral pH 7.2 than at pH 4.6 by cathepsin B; these substrates consisted of Z-Arg-Lys–AMC, Z-Lys-Lys–AMC, Z-Lys-Arg–AMC, and Z-Arg-Arg–AMC (Figure 4c). Z-Arg-Lys–AMC and Z-Arg-Arg–AMC had the highest ratio of pH 7.2/pH 4.6 activities (Figure 4d). Furthermore, acid pH preferring substrates consisted of Z-Glu-Lys–AMC and Z-Glu-Arg–AMC with Glu at the P2 position (Figure 4c). Z-Glu-Lys–AMC displayed the highest ratio of pH 4.6/pH 7.2 activities, indicating preference for pH 4.6 cathepsin B activity (Figure 4d).

Substrate concentration studies showed that at pH 7.2, cathepsin B displayed preference for the Z-Arg-Lys-AMC substrate, shown by the greater rate of hydrolysis of this substrate at pH 7.2 compared to pH 4.6, as illustrated by  $k_{cat}/K_m$  values (Figure 5a). At pH 4.6, cathepsin B preferred the Z-Glu-Lys-AMC substrate (Figure 5b), shown by the more rapid rate of hydrolysis at pH 4.6 over pH 7.2. In contrast, Z-Phe-Arg-AMC was hydrolyzed at similar rates by cathepsin B at both pH 4.6 and 7.2 (Figure 5c).

The complete pH profiles were assessed for the pH-selective substrates Z-Arg-Lys–AMC and Z-Glu-Lys–AMC and the non-pH-selective substrate Z-Phe-Arg–AMC (Figure 6). Hydrolysis of Z-Arg-Lys–AMC was maximal at pH 7.8, with >50% activity occurring between pH 6.2 to pH 8.5, indicating that Z-Arg-Lys–AMC is a selective neutral pH substrate of cathepsin B. In contrast, Z-Glu-Lys–AMC was optimally hydrolyzed at pH 4.6, with >50% activity occurring at pH 3.6



**Figure 6.** Cathepsin B pH-selective substrates Z-Arg-Lys-AMC and Z-Glu-Lys-AMC and the non-pH-selective substrate Z-Phe-Arg-AMC. The pH profiles cathepsin B activity with the substrates Z-Arg-Lys-AMC, Z-Glu-Lys-AMC, and Z-Phe-Arg-AMC were assessed at pH 2 to 9, with substrate concentrations at 60  $\mu$ M. Data points are shown as the mean  $\pm$  SEM (n = 3). The pH curves are also illustrated for cathepsin B activity expressed as AMC RFU/s (Figure S3).


to pH 5.6, indicating that Z-Glu-Lys–AMC is a selective acidic pH substrate. Z-Phe-Arg–AMC was hydrolyzed across a wide pH range with 50% of the maximum activity occurring between pH 3.8 and 8.6. These data clearly show that cathepsin B has distinct enzymatic properties at pH 4.6 and pH 7.2, and these differences can be exploited by rational design of pH-selective substrates.

The peptidic substrates were assessed for specificity for related lysosomal cysteine cathepsin proteases. Z-Arg-Lys–AMC selectively monitored cathepsin B activity primarily at pH 7.2 and showed no activity for cathepsin L or cathepsin V at pH 7.2 (Figure S4). Z-Glu-Lys–AMC was selective for cathepsin B activity at pH 4.6 and displayed no activity for cathepsins L or V. In contrast, Z-Phe-Arg–AMC was hydrolyzed by cathepsin B at both pH conditions, and this substrate was also cleaved by cathepsins L and V at pH 4.6.

Z-Arg-Lys-AOMK and Z-Glu-Lys-AOMK Inhibitors of Cathepsin B. The strategy to incorporate the AOMK warhead to replace the AMC group of the peptide-AMC substrates<sup>56,61-63</sup> was utilized to design and synthesize the Z-Arg-Lys-AOMK and Z-Glu-Lys-AOMK peptidic inhibitors (Figure S5). Z-Arg-Lys–AOMK displayed selective inhibition of cathepsin B at pH 7.2 compared to pH 4.6 (Figure 7a and Table 1). Determination of kinetic constants showed that Z-Arg-Lys–AOMK was a potent inhibitor with  $K_{\rm I}$  value of 130 nM at pH 7.2 but was less effective at pH 4.6 with a  $K_{\rm I}$  of 15000 nM at pH 4.6 (Table 1). The  $K_{\rm I}$  values show that this inhibitor displays 115-fold greater potency at pH 7.2 compared to pH 4.6. The  $k_{\rm inact}/K_{\rm I}$  constant was  $1.1 \times 10^5$  M<sup>-1</sup> s<sup>-1</sup> at pH 7.2 and  $1.8 \times 10^3$  M<sup>-1</sup> s<sup>-1</sup> at pH 4.6 (Table 1). The inhibitory effectiveness of Z-Arg-Lys–AOMK was also illustrated by its low IC<sub>50</sub> value of 20 nM, compared to its lower effectiveness at pH 4.6 with IC<sub>50</sub> value of 1500 nM. These kinetic studies illustrate that Z-Arg-Lys–AOMK is a potent neutral pH inhibitor of cathepsin B.

Compared to Z-Arg-Lys–AOMK, Z-Glu-Lys–AOMK displayed less effective inhibition of cathepsin B at both pH 7.2 and pH 4.6 (Figure 7b and Table 1). Kinetic analyses showed that Z-Glu-Lys–AOMK had  $K_{\rm I}$  values of 2300 nM and 7900 nM at pH 7.2 and pH 4.6, respectively (Table 1). The  $k_{\rm inact}/K_{\rm I}$  values for this inhibitor were  $8.2 \times 10^3$  M<sup>-1</sup> s<sup>-1</sup> and 2.0  $\times 10^3$  M<sup>-1</sup> s<sup>-1</sup> at pH 7.2 and pH 4.6, respectively (Table 1). These data showed that Z-Glu-Lys–AOMK was about 3.5-fold more potent at pH 7.2 compared to pH 4.6, with  $K_{\rm I}$  values for both pHs at micromolar levels. IC<sub>50</sub> values of 320 nM and 1100 nM for pH 7.2 and 4.6, respectively, were of similar orders of magnitude. The micromolar levels of Z-Glu-Lys–AOMK for inhibition at both pHs were less effective than the nanomolar levels of Z-Arg-Lys–AOMK for neutral pH inhibition of cathepsin B.

Neutral pH-Selective Inhibition of Peptide Library Cleavages by Z-Arg-Lys-AOMK. To further validate the neutral pH selectivity of Z-Arg-Lys-AOMK inhibition, cathepsin B was preincubated with this inhibitor at 64 nM at pH 7.2 and pH 4.6, and proteolytic activity was assessed using the 228-member peptide library in MSP-MS assays. The 64 nM concentration of Z-Arg-Lys-AOMK was chosen because it reduced cathepsin B activity with Z-Phe-Arg-AMC as substrate by 93% at pH 7.2 and by 5% at pH 4.6 (Figure 8). At pH 7.2, Z-Arg-Lys-AOMK completely inhibited peptide cleavages by cathepsin B after 1 h incubation (Figure 8a).




**Figure 7.** Z-Arg-Lys–AOMK and Z-Glu-Lys–AOMK inhibitors of cathepsin B at neutral pH compared to acidic pH conditions. (a) Z-Arg-Lys–AOMK inhibitor. Z-Arg-Lys–AOMK inhibitor. Z-Arg-Lys–AOMK inhibitor of cathepsin B was assessed at different inhibitor concentrations to determine  $IC_{50}$  values at pH 7.2 and pH 4.6. Z-Phe-Arg–AMC was used as substrate for cathepsin B assays. (b) Z-Glu-Lys–AOMK inhibitor. The inhibitor Z-Glu-Lys–AOMK at different concentrations was assessed for  $IC_{50}$  values at pH 4.6 and pH 7.2.

#### Table 1. Kinetic Properties of Z-Arg-Lys-AOMK and Z-Glu-Lys-AOMK Inhibitors<sup>a</sup>

	Z-Arg-Lys-AOMK		Z-Glu-Lys–AOMK	
kinetic constant	pH 4.6	pH 7.2	pH 4.6	рН 7.2
$K_{\rm I}$ (nM)	$15000 \pm 6000$	$130 \pm 50$	$7900 \pm 830$	$2300 \pm 620$
$k_{\rm inact}/K_{\rm I}~({ m M}^{-1}~{ m s}^{-1})$	$1.8 \times 10^{3}$	$110 \times 10^{3}$	$2.0 \times 10^{3}$	$8.2 \times 10^{3}$
$IC_{50}$ (nM)	$1500 \pm 650$	20 + 8.3	$1100 \pm 480$	$320 \pm 45$

 ${}^{a}K_{1}$ ,  $k_{\text{inact}}/K_{\text{L}}$ , and  $\text{IC}_{50}$  values for the irreversible inhibitors of cathepsin B were determined as explained in the methods;  $k_{\text{obs}}$  values were determined by plots of cathepsin B activity in time courses with different inhibitor concentrations with curve fitting  $Y = Y_0 e^{(-k_{\text{obs}}X)}$ , where  $Y_0$  is the activity for the control with no inhibitor condition, Y is the activity in the presence of inhibitor, and X is time.  $K_{\text{I}}$  and  $k_{\text{inact}}$  values were calculated from  $k_{\text{obs}}$  values with the equation  $k_{\text{obs}} = k_{\text{inact}}[I]/(K_{\text{I}} + [I])$  (graphs shown in Figure S6), where [I] is inhibitor concentration,  $K_{\text{I}}$  is the inhibitor concentration (*x*-axis) at which  $y = k_{\text{inact}}/2$ , and  $k_{\text{inact}}$  is the maximum rate of inactivation at saturating inhibitor concentrations.  $K_{\text{I}}$  and  $\text{IC}_{50}$  values are expressed as the mean  $\pm$  SD (n = 4, n = 6, respectively)





**Figure 8.** Z-Arg-Lys–AOMK selectively inhibits cathepsin B cleavage of peptide substrates at pH 7.2 compared to pH 4.6, assessed by MSP-MS. (a) Z-Arg-Lys–AOMK (64 nM) at pH 7.2 inhibits cathepsin B cleavage of peptide library substrates assessed by MSP-MS. The inhibitor concentration was selected for ~90% inhibition at pH 7.2 (using Z-F-R–AMC substrate), which consisted of 64 nM Z-Arg-Lys–AOMK (93% inhibition at pH 7.2). MSP-MS assays analyzed the cleavage products generated from the peptide library by LC-MS/MS identification and quantification. The relative quantities of each peptide product generated in the absence of inhibitor or in the presence of inhibitor were plotted as the fold-change of each peptide product relative to no enzyme activity control. (b) Z-Arg-Lys–AOMK (64 nM) at pH 4.6 does not inhibit cathepsin B cleavage of peptide library substrates assessed by MSP-MS. Cathepsin B was incubated without and with the inhibitor at pH 4.6 for MSP-MS analyses of peptide products. The MSP-MS procedure and inhibitor concentrations are described in the panel a description.


Table 2. Specificity of Z-Arg-Lys–AOMK and Z-Glu-Lys–AOMK for Inhibition of Cathepsin B Compared to Other Cysteine	
Cathepsins <sup>4</sup>	

	Z-Arg-Lys-AOMK IC <sub>50</sub> (nM)		Z-Glu-Lys–AOMK IC <sub>50</sub> (nM)	
protease	pH 4.6	pH 7.2	pH 4.6	pH 7.2
cathepsin B	1500	20	1100	320
cathepsin C	>16000(6%)	850	8600	12000
cathepsin H	Ь	>16000(29%)	Ь	Ь
cathepsin K	Ь	>16000(31%)	>16000(10%)	Ь
cathepsin L	>16000(32%)	с	>16000(23%)	с
cathepsin S	>16000(13%)	2200	>16000(26%)	>16000(30%)
cathepsin V	>16000(63%)	440	1900	>16000(10%)
cathepsin X	>16000(21%)	с	Ь	С

<sup>*a*</sup>Inhibitors were evaluated for protease specificity among the 8 cysteine cathepsins, achieved by monitoring the activity of each enzyme in the presence of a range of inhibitor concentrations from 0.5 nM to 16  $\mu$ M (without preincubation). IC<sub>50</sub> values were generated for the inhibitors Z-Arg-Lys–AOMK and Z-Glu-Lys–AOMK for each of the cysteine cathepsin enzymes. IC<sub>50</sub> values are indicated as >16000 nM when partial inhibition was observed (% inhibition is shown in parentheses). <sup>*b*</sup>No inhibition at 16000 nM inhibitor. <sup>*c*</sup>Enzyme had no activity at the indicated pH.

However, at pH 4.6, Z-Arg-Lys-AOMK (64 nM) did not inhibit cathepsin B formation of peptide products (Figure 8b). These findings show that Z-Arg-Lys-AOMK selectively inhibits cathepsin B cleavage of peptides at neutral cytosolic pH compared to acidic lysosomal pH conditions.

Irreversible Mechanism of Z-Arg-Lys-AOMK and Z-Glu-Lys-AOMK Inhibitors. The irreversible mechanism of the inhibitors was demonstrated by preincubation of each inhibitor with cathepsin B, followed by dilution and activity measurements (Figure S7). Control enzyme without inhibitor displayed a linear time-dependent progression of proteolytic activity. Preincubation with Z-Arg-Lys–AOMK or Z-Glu-Lys– AOMK at pH 7.2 and pH 4.6, respectively, resulted in no



**Figure 9.** Model of Z-Arg-Lys–AOMK binding to cathepsin B at neutral pH 7.2: interaction of enzyme Glu245 with P2 Arg. (a) Model of the Z-Arg-Lys–AOMK inhibitor docking to cathepsin B at pH 7.2. Modeling of Z-Arg-Lys–AOMK binding to the active site of the cathepsin B structure is illustrated, achieved by the MOE software using the cathepsin B structure of PDB 1QDQ as template for analyses at pH 7.2.<sup>60</sup> The P1 Lys residue of Z-Arg-Lys–AOMK interacts with the enzyme S1 subsite, shown in the blue region. The P2 Arg residue of the inhibitor interacts with the enzyme S2 subsite region, shown in orange. The inhibitor AOMK warhead docking to the enzyme region corresponds to the S1' and S2' subsites, shown in gray. (b) Two-dimensional illustration of Z-Arg-Lys–AOMK and cathepsin B binding interactions at pH 7.2. The peptidic Z-Arg-Lys–AOMK inhibitor interacts with the active site of cathepsin B, modeled by MOE. The P2 Arg residue of the Z-Arg-Lys–AOMK shows a strong polar interaction with the Glu245 carboxylate of the S2 pocket of the enzyme. The P1 Lys and P2 Arg residues of the S1 subsite.<sup>60,68</sup> The AOMK warhead resides within 3.75 Å from the catalytic Cys29 nucleophile, suggesting a binding mode for irreversible inhibition; the AOMK group occupies the S1' region near the occluding loop. The Z group (benzyloxycarbonyl) appears partially solvent exposed and extended from the S2 region.

cathepsin B activity after dilution of the inhibitors, indicating the irreversible mechanism of these inhibitors.

Z-Arg-Lys–AOMK and Z-Glu-Lys–AOMK Specifically Inhibit Cathepsin B Compared to Other Cysteine Cathepsins. At pH 7.2, Z-Arg-Lys–AOMK inhibited cathepsin B with an IC<sub>50</sub> of 20 nM, which was more potent by 22-fold, 110fold, and 43-fold than cathepsin V (IC<sub>50</sub> = 440 nM), cathepsin S (IC<sub>50</sub> = 2200 nM), and cathepsin C (IC<sub>50</sub> = 850 nM) inhibition (Table 2). At pH 7.2, cathepsins K and H were minimally inhibited by Z-Arg-Lys–AOMK at 16  $\mu$ M. At pH 4.6, Z-Arg-Lys–AOMK inhibited cathepsin B with IC<sub>50</sub> of 1500 nM, and at 16  $\mu$ M, this inhibitor showed minimal inhibition of cathepsins L, V, S, X, and C, and no inhibition of cathepsin K or cathepsin H.

Z-Glu-Lys–AOMK also demonstrated specific inhibition of cathepsin B compared to other cysteine cathepsins (Table 2). At pH 7.2, the inhibitor was 38-fold more potent for cathepsin B (IC<sub>50</sub> = 320 nM) than cathepsin C (IC<sub>50</sub> = 12000 nM). At pH 4.6, weak inhibition of cathepsin V (IC<sub>50</sub> = 1900 nM) and cathepsin C (IC<sub>50</sub> = 8600 nM) occurred, while the other cathepsin enzymes tested were minimally inhibited or not inhibited by Z-Glu-Lys–AOMK (at 16  $\mu$ M) at either pH condition.

These data illustrate the high specificity of Z-Arg-Lys– AOMK and Z-Glu-Lys–AOMK inhibitors for cathepsin B over other members of the cysteine cathepsin family.

Molecular Docking of Z-Arg-Lys-AOMK to Cathepsin B at Neutral pH 7.2: Interaction of Glu245 of the Enzyme with P2 Arg. Modeling of Z-Arg-Lys-AOMK binding interactions to cathepsin B was assessed by the Molecular Operating Environment (MOE) software.<sup>64,65</sup> MOE generated a representation of inhibitor binding to the active site of human cathepsin B (PDB: 1QDQ)<sup>60</sup> at pH 7.2 consisting of P2 and P1 residues of the peptidic inhibitor interacting with

the S2 and S1 subsites of the enzyme, according to the Schechter-Berger nomenclature<sup>66</sup> (Figure 9). The P2 Arg residue of the Z-Arg-Lys-AOMK shows a strong polar interaction with the carboxylate of Glu245 in the S2 subsite of the enzyme. Glu245 at pH 7.2 is negatively charged (based on its  $pK_a$  of 5.1)<sup>67</sup> and is predicted to interact with the positively charged P2 Arg of the inhibitor at neutral pH. The P1 Lys residue of the inhibitor interacts with Glu122 and Asn72 of the enzyme S1 pocket.<sup>60,68</sup> The AOMK warhead occupies the S1' region near the occluding loop; furthermore, the AOMK carbon atom resides less than 3.4 Å from the catalytic Cys29 nucleophile, suggesting a binding mode for irreversible inhibition. The Z group (benzyloxycarbonyl) appears partially solvent exposed and extended from the S2 region. In contrast, a pH 4.6 model of Z-Arg-Lys-AOMK docking to cathepsin B showed a lack of Glu245 interaction with the Arg moiety of this inhibitor (Figure S8). These features illustrate a model of Z-Arg-Lys-AOMK binding to the active site of cathepsin B at neutral pH.

At pH 4.6, Z-Arg-Lys–AOMK docking by MOE modeling showed no interactions of Glu245 (of the enzyme) with the Arg of this inhibitor (Figure S9), which contrasts with Glu245 interactions with Arg of Z-Arg-Lys–AOMK at pH 7.2. MOE modeling suggests Glu245 interaction with Z-Arg-Lys–AOMK at pH 7.2 but no interaction with Z-Glu-Lys–AOMK. MOE calculations of the inhibitor binding energies to cathepsin B at pH 7.2 and pH 4.6 show more favorable interactions of Z-Arg-Lys–AOMK at pH 7.2 compared to pH 4.6 (Table 3). These binding energies were estimated based on interactions of enzyme active site residues with the inhibitors.

With respect to Z-Glu-Lys–AOMK, MOE shows that Z-Glu-Lys–AOMK lacks interactions with the Glu245 of the S2 pocket of cathepsin B (Figure S9). Furthermore, similar binding energies were calculated at pH 7.2 and pH 4.6 for Z-

Table 3. Binding Energies of Z-Arg-Lys–AOMK and Z-Glu-Lys–AOMK to Cathepsin B at Neutral pH 7.2 and Acidic pH  $4.6^a$ 

	binding energy (kcal/mol)	
inhibitor	pH 7.2	pH 4.6
Z-Arg-Lys-AOMK	-55.5	-26.2
Z-Glu-Lys-AOMK	-52.3	-55.9

<sup>*a*</sup>For Z-Arg-Lys–AOMK, the more negative binding energy calculated for pH 7.2 compared to pH 4.6 indicates a more favorable interaction of this inhibitor to cathepsin B at pH 7.2. These calculations are made with Glu245 protonated at pH 4.6. For Z-Glu-Lys–AOMK, the equivalent binding energies calculated for pH 7.2 and pH 4.6 indicate a similar interaction of this inhibitor to cathepsin B at these two pH conditions.

Glu-Lys-AOMK (Table 3), suggesting that this inhibitor was not pH-selective. This lack of pH selectivity is supported by our inhibition studies (Table 1). The MOE modeling implicates the importance of Glu245 of cathepsin B for effectiveness of the neutral pH inhibitor Z-Arg-Lys-AOMK.

Z-Arg-Lys–AOMK Inhibition of Intracellular Cathepsin B and Cell Permeability. Z-Arg-Lys–AOMK was evaluated for its ability to inhibit cathepsin B activity in human neuroblastoma cell lysate using Z-Arg-Arg–AMC substrate. Proteolytic activity in the cell lysate was completely inhibited by Z-Arg-Lys–AOMK (1  $\mu$ M) and by CA-074 (1  $\mu$ M), a specific inhibitor of cathepsin B<sup>69</sup> (Figure 10a). These data show that Z-Arg-Lys–AOMK and CA-074 inactivate cathepsin B.

The cell permeability of Z-Arg-Lys–AOMK was evaluated by incubation of neuroblastoma cells with this inhibitor (50




Figure 10. Z-Arg-Lys-AOMK inhibition of cathepsin B in human neuroblastoma cells. (a) Cell homogenates assayed for cathepsin B activity in the presence of inhibitors. Homogenates of SHSY5Y human neuroblastoma cells were prepared as described in the Methods and Materials. Cathepsin B activity in the homogenate was assayed with Z-Arg-Arg-AMC substrate in the presence of Z-Arg-Lys–AOMK or CA-074 (1  $\mu$ M each). Assays were conducted at high concentrations of inhibitors to completely inhibit activity; assays were conducted at pH 5.5 because this is a routine pH used to assay this enzyme in the literature.<sup>71,72</sup> Cathepsin B activity was expressed as nmol AMC/( $\mu$ g/min), mean  $\pm$  SD (\*p < 0.05 by Student's t test, n =3). (b) Cells incubated with inhibitors and assay of cathepsin B activity. Human neuroblastoma cells were incubated with Z-Arg-Lys-AOMK or CA-074Me (50  $\mu$ M each) for 6 h at 37 °C. Cells were homogenized as described in the Methods and Materials, and cathepsin B was assayed with Z-Arg-Arg-AMC substrate. Cathepsin B activity was expressed as nmol  $\tilde{AMC}/(\mu g/min)$  and shown as mean + SD (\*p < 0.05 by Student's *t* test, n = 6).

 $\mu$ M) for 6 h. Cells were also incubated with CA-074Me (50  $\mu$ M); CA-074Me is known to enter cells and be converted by esterases to the potent CA-074 inhibitor of cathepsin B.<sup>70</sup> After incubation, cells were washed, and homogenates were assayed for cathepsin B activity with Z-Arg-AMC substrate. Z-Arg-Lys-AOMK and CA-074Me completely inhibited cellular cathepsin B activity (Figure 10b). These results demonstrate that the Z-Arg-Lys-AOMK is cell permeable and inhibits intracellular cathepsin B.

Discussion. In this study, we designed and developed a neutral pH-selective inhibitor, Z-Arg-Lys-AOMK, of cathepsin B based on the enzyme's distinct substrate cleavage properties observed at neutral pH 7.2 compared to acidic pH 4.6. Cathepsin B functions at the neutral pH locations of the cytosol and extracellular environments in brain disorders<sup>12–25</sup> and human diseases of different physiological systems,<sup>26-32</sup> which contrasts with the normal location of cathepsin B in lysosomes of acidic pH. Development of the neutral pH inhibitor was based on the hypothesis that the unique pHdependent cleavage properties of cathepsin B may provide the basis for the design of selective neutral pH inhibitors. Specifically, the differential cleavage properties of cathepsin B at neutral pH compared to acidic pH were revealed by MSP-MS substrate profiling, which utilizes a peptide library containing all neighbor and near-neighbor amino acid combinations. MSP-MS assays revealed preferences of cathepsin B for residues at the P2 and P1 positions of the cleavage site (P1- $\downarrow$ P1'). The P2 position prefers Glu (E) at acidic pH, but prefers a basic residue Arg (R) at neutral pH. At the P1 position, basic residues are preferred at both neutral and acidic pHs. These cleavage properties led to the design of Z-Arg-Lys-AMC as a neutral pH 7.2 selective substrate and Z-Glu-Lys-AMC as an acidic pH 4.6 selective substrate. Inhibitors were generated by synthesis of these dipeptide substrates with the AOMK (acyloxymethyl ketone) warhead. Z-Arg-Lys-AOMK was found to be an effective irreversible inhibitor of cathepsin B at neutral pH with nanomolar potency. Z-Arg-Lys-AOMK displays 100-fold more potent inhibition of cathepsin B at neutral pH compared to acidic pH. These findings indicate that Z-Arg-Lys-AOMK is a neutral pH inhibitor of cathepsin B, thus validating our hypothesis that substrate specificity differences can be utilized for rational design of pH-selective inhibitors. Surprisingly, Z-Glu-Lys-AOMK was not selective for inhibition at acid pH; thus, addition of reactive warheads to peptide substrates may not always retain pH selectivity. Nonetheless, these findings demonstrate that pH-selective inhibitors of cathepsin B can be developed based on its pH-dependent cleavage properties.

A notable finding of this study is that cathepsin B displays similar stability at both neutral pH 7.2 and acidic pH 4.6 conditions. While cathepsin B normally functions at the acidic pH 4.6 within lysosomes, we show that cathepsin B has similar stability at both neutral and acidic pH conditions. Cathepsin B was more stable at pH 7.2 than at pH 4.6 for up to 2 h at RT (RT). Using conditions that maintain stability, cathepsin B activity in this study was conducted with RT incubation up to 60 min for MSP-MS assays and up to 30 min for fluorogenic assays. Studies at 37 °C were also conducted and showed similar stability studies complement reports in the field that cathepsin B becomes inactivated with time at neutral and alkaline conditions of pH 7.0–9.5.<sup>\$1,73–75</sup> Our data provides new information that similar stability and inactivation properties of cathepsin B are observed at pH 7.2 and pH 4.6.

Cathepsin B is known to cleave folded protein substrates such as MARCKS, collagen, and thyroglobulin<sup>48,76–78</sup> via its endopeptidase activity. Using a substrate library of synthetic peptides that lack secondary structure, we can detect both endoprotease and exoprotease activity for any protease. We show that cathepsin B is primarily a dipeptidyl carboxypeptidase enzyme, and sequential removal of dipeptidyl carboxypeptidase activity of protein substrates using traditional gel shift assays is difficult as the molecular weight changes are minor. However, using mass spectrometry, hydrolysis of peptide substrates into shorter products can be readily detected and quantified.

The role of the occluding loop for exopeptidase compared to endopeptidase activities of cathepsin B has been demonstrated by deletion mutagenesis of the loop domain, which resulted in the absence of exopeptidase activity and the presence of only endopeptidase activity.<sup>79</sup> Furthermore, site-directed mutagenesis of selected residues within the occluding loop resulted in increased endopeptidase activity.<sup>80</sup> These studies indicate that the occluding loop regulates the exopeptidase and endopeptidase activities of cathepsin B.

Cathepsin B activity is typically monitored with Z-Phe-Arg– AMC and Z-Arg-Arg–AMC fluorogenic substrates for endopeptidase activity.<sup>81–83</sup> However, use of extended peptide substrates that can be cleaved by either endopeptidases or exopeptidases in the MSP-MS cleavage analyses illustrated the predominant exopeptidase activity of cathepsin B at both neutral and acidic pHs. These data demonstrate that these commonly used peptide–AMC substrates monitor both the dipeptidyl carboxypeptidase and endopeptidase activities of cathepsin B.

The differential cleavage profiles of cathepsin B at neutral pH 7.2 and acidic pH 4.6 conditions by MSP-MS provided the basis for development of pH-selective peptide-AMC substrates. At the P2 position, cathepsin B demonstrated preference for Glu at pH 4.6, but at pH 7.2, the enzyme preferred basic residues of Arg and Lys. At the P1 position, cathepsin B showed preference for basic residues Arg or Lys residues at acidic and neutral pH conditions. Prior studies of cathepsin B cleavage properties at pH  $5.5^{71,72}$  showed that the enzyme prefers P2 residues of Arg and Lys, but not Glu, and prefers P1 residues of Arg and Lys. These findings suggest that the cleavage specificity of cathepsin B at pH  $5.5^{71,72}$  resembles that of cathepsin B at pH 7.2. But cathepsin B at pH 5.5 did not display the pH 4.6 preference of the enzyme for Glu as the P2 residue found in this study. These findings together demonstrate pH-dependent cleavage specificities of cathepsin B.

The differential P2 and P1 residue preferences of cathepsin B were utilized to design and assess pH-selective peptide– AMC substrates. The Z-Arg-Lys–AMC substrate displayed high preference for neutral pH cathepsin B compared to several related substrates tested. The presence of Glu at the P2 position of Z-Glu-Lys–AMC was the rationale for its function as a selective substrate for acidic pH 4.6 cathepsin B. These findings demonstrate that the pH-dependent cleavage properties can provide the basis for design of pH-selective substrates of cathepsin B.

Significantly, design and synthesis of the Z-Arg-Lys-AOMK inhibitor resulted in selective and potent inhibition of neutral

pH cathepsin B activity; this inhibitor was designed based on the neutral pH-selective Z-Arg-Lys-AMC substrate. At pH 7.2, the Z-Arg-Lys-AOMK inhibitor displayed potent inhibition with a low  $K_{I}$  of 130 nM, but it was less effective at pH 4.6 with a higher  $K_{\rm I}$  of 15000 nM. These results show that Z-Arg-Lys-AOMK is 115 times more potent at neutral pH 7.2 compared to acidic pH 4.6. Z-Arg-Lys-AOMK was shown to be an irreversible inhibitor with specificity for inhibition of cathepsin B over other cysteine cathepsins (cathepsins L, V, S, X, K, C, and H). Docking of Z-Arg-Lys-AOMK to cathepsin B at pH 7.2 was modeled by MOE, which illustrated the active site binding features of the inhibitor. The model featured the ionic interaction of the positively charged P2 Arg residue of the peptidic inhibitor with the negatively charged Glu245 residue of the S2 subsite of cathepsin B at pH 7.2, which was absent at pH 4.6. This proposed interaction is consistent with studies showing the importance of Glu245 for interactions of the enzyme with the P2 residue of peptides.<sup>60,68</sup> Future studies of inhibitor and enzyme binding interactions can be gained through in-depth structural and computational investigation. Importantly, the findings of this study demonstrate Z-Arg-Lys-AOMK as a novel inhibitor that selectively and potently inhibits cathepsin B at neutral pH.

The Z-Glu-Lys–AOMK inhibitor displayed inhibition of neutral and acidic cathepsin B at micromolar levels of inhibitor with only a 3-fold difference in potency, even though the substrate Z-Glu-Lys–AMC preferentially detected acidic pH cathepsin B activity (rather than neutral pH activity). It appears that substitution of AOMK for the AMC of the Glu-Lys dipeptide removed its pH selectivity. It is noted that Lys at the P1 position is preferred for neutral pH cathepsin B activity, and thus, the Lys at P1 may influence the inhibitor properties of Z-Glu-Lys–AOMK. These data show that a pH-selective peptide–AMC substrate may not always lead to a pH-selective peptidic AOMK inhibitor. Nonetheless, Z-Glu-Lys–AOMK represents a novel inhibitor of cathepsin B.

The neutral, cytosolic pH functions of cathepsin B due to lysosomal leakage occur in brain disorders and in numerous human diseases involving physiological organ systems.<sup>12-32</sup> Lysosomal leakage results in translocation of cathepsin B from the lysosome to the cytosol where cathepsin B initiates apoptotic cell death<sup>33–36</sup> and activates IL-1 $\beta$  production in inflammation.<sup>31,37–39</sup> Cathepsin B leakage to the cytosol occurs in brain disorders: AD,<sup>14–17</sup> TBI and ischemia,<sup>18–21</sup> Parkinson's disease<sup>22,23</sup>, Niemann–Pick disease and lysosomal storage disorders,<sup>24,25</sup> and pneumococcal meningitis.<sup>84</sup> These neurodegenerative disorders also involve calpain in membrane permeabilization of lysosomes, allowing cathepsin B to exit the lysosome and enter the cytosol, known as the calpaincathepsin hypothesis.<sup>85,86</sup> Other human diseases that involve lysosomal leakage of cathepsin B include autoinflammatory disease,<sup>26,27</sup> atherosclerosis,<sup>28,29</sup> and pancreatitis.<sup>30</sup> In addition to the pathogenic function of cathepsin B in the cytosol, cathepsin B also functions at neutral pH in extracellular locations in cancer<sup>42–46</sup> and rheumatoid arthritis<sup>47</sup> and nuclear locations in thyroid carcinoma,<sup>49</sup> in chromosome segregation,<sup>50</sup> and in the thyroid follicle.<sup>48</sup> In cancer, the tumor environment has been found to be at pH 6.8 due to the Warburg effect for tumor acidosis;<sup>87,88</sup> the Z-Arg-Lys–AOMK inhibitor was also found to be effective at pH 6.8 with an IC<sub>50</sub> value of 22 nM (Figure S10). Overall, the prevalence of cytosolic cathepsin B in human diseases emphasizes the critical

importance of this study to gain an understanding of the unique neutral pH properties of cathepsin B compared to its normal acidic lysosomal features.

In summary, the novel pH-dependent cleavage properties of the major dipeptidyl carboxypeptidase activity of cathepsin B were revealed by MSP-MS substrate profiling that led to design of pH-selective substrates and novel peptidic AOMK inhibitors. Notably, Z-Arg-Lys-AOMK was demonstrated as a potent, neutral pH inhibitor of cathepsin B. These findings demonstrate that the distinct pH-dependent cleavage properties of cathepsin B can provide the basis for development of a neutral pH inhibitor with more than 100-fold greater potency at pH 7.2 compared to pH 4.6. The novel Z-Arg-Lys-AOMK inhibitor may allow future studies to probe the role of pathogenic neutral pH cathepsin B functions that participate in brain disorders and human diseases.

# METHODS AND MATERIALS

Enzymes, Peptides, and Reagents. Recombinant human cathepsin B and cathepsin proteases were obtained from R&D Systems (Minneapolis, MN) or Abcam (Cambridge, MA), consisting of cathepsin B (R&D no. 953-CY-010), cathepsin L (R&D no. 952-CY-010), cathepsin V (R&D no. 1080-CY-010), cathepsin S (R&D no. 1183-CY-010), cathepsin K (Abcam no. ab157067), cathepsin C (R&D no. 1071-CY-010), and cathepsin H (R&D no. 75116-CY-010). The design and synthesis of the 228 14-mer peptides used for MSP-MS assays have been described previously.<sup>53,89</sup> MSP-MS assays utilized low-bind 600 µL microtubes (Corning, Reynosa, MX), dithiothreitol (DTT; Promega no. V351, Madison, WI), urea (Teknova no. U2222, Hollister, CA), HPLC-grade water (Fisher Chemical no. W6-4), citric acid monohydrate (Merck no. 1.00244.0500, Burlington, MA), sodium phosphate dibasic anhydrous (EMD no. SX-072305, Burlington, MA), sodium acetate (Fisher Scientific no. BP-333-500, Fair Lawn, NJ), EDTA (Calbiochem no. 324503, Burlington, MA), sodium chloride (Fisher Chemical no. S271-1, Pittsburgh, PA), acetonitrile (Fisher Chemical no. A955-4, Pittsburgh, PA), formic acid (FA; Fisher Chemical no. A117-50, Pittsburgh, PA), trifluoroacetic acid (TFA; Fisher Chemical no. A116-50, Pittsburgh, PA), C18 LTS Tips (Rainin no. PT-LC18-960, Oakland, CA), C18 for SPE stage-tips (3 M company no. 2215-C18, Maplewood, MN), and BEH C18 packing material (Waters Corporation no. 186004661, Milford, MA). Fluorogenic peptide substrates were obtained from Bachem, Torrance, CA, and consisted of Abz-Gly-Ile-Val-Arg-Ala-Lys(Dnp)-OH (no. 4049308), Z-Arg-Arg-AMC (no. 4004789), Arg-AMC (no. I-1050), and Gly-Arg-AMC (no. 4002196). Z-Phe-Arg-AMC was purchased from Anaspec, Fremont, CA (no. AS-24096). Z-Lys-Lys-AMC, Z-Lys-Arg-AMC, Z-Arg-Lys-AMC, Z-Glu-Lys-AMC, and Z-Glu-Arg-AMC were custom synthesized by Genscript (Piscataway, NJ). MCA-Arg-Pro-Pro-Gly-Phe-Ser-Ala-Phe-Lys(Dnp)OH was from CPC Scientific, San Jose, CA (no. AMYD-111A). E64c was from Selleckchem (Houston, TX); CA-074 and CA-074Me were from SigmaMillipore (Burlington, MA). Cell culture media components MEMalpha, F-12K, and FBS were from ThermoFisher (Watham, MA), and F-12K was from ATCC (Manassas, VA). The DC protein kit was from Biorad (Hercules, CA).

**Cathepsin B Activity and Stability.** Recombinant human procathepsin B was activated to mature cathepsin B by incubation at 37 °C for 30 min in activation buffer (20 mM Na-acetate (pH 5.5), 1 mM EDTA, 5 mM DTT, 100 mM NaCl). To examine enzyme activity and stability, cathepsin B was preincubated at pH 7.2 or pH 4.6 at room temperature (RT, 27 °C) and 37 °C for times of 0.5, 1, 2, 3, and 4 h. Cathepsin B activity was then assayed in 50 mM citrate phosphate at pH 7.2 or pH 4.6, 40 mM Z-Phe-Arg–AMC substrate, 1 mM EDTA, 100 mM NaCl, 5 mM DTT, and 0.01% Tween20 with incubation at RT for 30 min. Cleavage of Z-Phe-Arg–AMC to generate fluorescent AMC was monitored at excitation 360 nm and emission 460 nm. Assays for each condition were conducted in triplicate, and the mean  $\pm$  SD values were calculated.

Cathepsin B Cleavage Site Analysis by Multiplex Substrate Profiling by Mass Spectrometry (MSP-MS). Cathepsin B activity (activated) was titrated with E64c to calculate the concentration of active cathepsin B. For MSP-MS assays, cathepsin B (0.1 ng/ $\mu$ L, activated) was incubated with a peptide library of 228 14-mer peptides, each at 0.5  $\mu$ M peptide, in buffer consisting of 50 mM citrate phosphate at pH 7.2 or pH 4.6, 1 mM EDTA, 100 mM NaCl, and 4 mM DTT (total volume of 46  $\mu$ L). After incubation for 15 and 60 min at 25 °C, 20  $\mu$ L aliquots were removed and combined with 80  $\mu$ L of 8 M urea. An inactivated cathepsin B control consisted of cathepsin B in assay buffer combined with 8 M urea for 60 min at 25 °C for denaturation, followed by addition of the peptide library. After incubation, samples were acidified by addition of 40  $\mu$ L of 2% FA, desalted using C18 LTS Tips (Rainin), evaporated to dryness in a vacuum centrifuge, and stored at -70 °C. Samples were resuspended in 20  $\mu$ L of 0.1% FA (solvent A), and 1  $\mu$ L was used for LC-MS/MS analysis. All MSP-MS conditions were conducted in quadruplicate assavs.

MSP-MS assay samples were then subjected to LC-MS/MS performed on a Q-Exactive mass spectrometer (Thermo) equipped with an Ultimate 3000 HPLC (Thermo Fisher). Peptides were separated by reverse phase chromatography on a C18 column (1.7  $\mu$ m bead size, 75  $\mu$ m × 20 cm, 65 °C) at a flow rate of 400 nL/min using solvent A (0.1% FA in water) and solvent B (0.1% FA in acetonitrile). LC separation was performed using a 50 min linear gradient of 5% to 30% solvent B followed by a 15 min linear gradient of 30% to 75% solvent B. Survey scans were recorded over a 200–2000 m/z range (70000 resolutions at 200 m/z, AGC target 1  $\times$  10<sup>6</sup>, 75 ms maximum). MS/MS was performed in data-dependent acquisition mode with HCD fragmentation (30 normalized collision energy) on the 10 most intense precursor ions (17500 resolutions at 200 m/z, AGC target  $5 \times 10^4$ , 120 ms maximum, dynamic exclusion 15 s). A technical report of the LC-MS/MS method is provided in Methods S1.

Peak integration and peptide data analysis were performed using PEAKS (v 8.5) software (Bioinformatics Solutions Inc.). A summary of the PEAKS search parameters is provided in the Methods S2. MS<sup>2</sup> data were searched against the 228-member tetradecapeptide library sequences, and a decoy search was conducted with sequences in reverse order. A precursor tolerance of 20 ppm and 0.01 Da for MS<sup>2</sup> fragments was defined. No protease digestion was specified. Data were filtered to 1% peptide false discovery rates with the target-decoy strategy. Peptide intensities were quantified, and data was normalized by Loess-G algorithm (http://normalyzer.immunoprot.lth.se/) and filtered by 0.5 peptide quality. Outliers from replicates were removed by Dixon's Q testing<sup>90</sup> when there were at least 3 replicate values found out of the 4 replicates for each condition for every peptide. Missing and zero values are imputed with random normally distributed numbers in the range of the average of the smallest 5% of the data  $\pm$  SD. An ANOVA test was performed for peptide data found in the three conditions of control, 15 min incubation, and 60 min incubation; those with p < 0.05 were considered for further analysis. Cleaved peptide products were defined as those with intensity scores of 8-fold or more above the quenched inactive cathepsin B, assessed using the ratio of log2(Cat.B/inactivated enzyme) for each peptide product. Ratios were evaluated for p <0.05 by 2-tailed homoscedastic t test (Methods S3 for "Workbook of MSP-MS data").

Analyses of MSP-MS Data for Cleavage Preferences of Cathepsin B by iceLogo. Evaluation of the frequencies of amino acids adjacent to the cleavage sites was conducted using the iceLogo software.<sup>91</sup> IceLogo analyses utilized (a) the "positive data set" consisting of the P2 to P2' amino acids that surround the cleavage sites between the 12th and 13th amino acid of the 14-mer peptides and (b) the "negative data set" consisting of the P2 to P2' amino acids for the 228 cleavage sites of the peptide library between the 12th and 13th amino acid. All positive and negative data are listed in Methods S3. Analyses involved Z-scores calculated by the equation  $X - \mu/\sigma$ ,

where X is the frequency of the amino acid in the experimental data set,  $\mu$  is the frequency of a particular amino acid at a specific position in the reference set (control "0" time), and  $\sigma$  is the standard deviation. Z-scores were utilized to generate iceLogo illustrations of the relative frequencies of amino acid residues at each of the P2 to P2' positions of the cleaved peptides where heights of the single letter amino acids represent "percent difference", defined as the difference in frequency for an amino acid appearing in the positive data set relative to the negative data set. Positive differences are shown above the midline, and negative differences are represented below the midline. Residues below the line shown in gray are those that were absent in the positive data set.

Synthesis of Z-Arg-Lys–AOMK and Z-Glu-Lys–AOMK inhibitors. Inhibitor synthesis was achieved in three steps via production of Fmoc-Lys(Boc)–AOMK, semicarbazide aminomethyl polystyrene resin (5), and Z-Arg-Lys–AOMK and Z-Glu-Lys–AOMK (illustrated in Figure S5).

For Fmoc-Lys(Boc)-AOMK synthesis, N-methylmorpholine (1.06 g, 10.5 mmol) and isobutyl chloroformate (1.434 g, 10.5 mmol) were added dropwise to a stirred solution of amino acid 1 (4.68 g, 10.0 mmol) in 100 mL of dry tetrahydrofuran (THF) in a 200 mL flame polished round-bottom flask at -10 °C. After 15 min, ethereal diazomethane was generated and distilled from Diazald (6.43 g, 30.0 mmol) in accordance to procedures outlined in the Aldrich Technical Bulletin al180 into stirred solution over the course of 30 min (AL-180) (Sigma-Aldrich Technical Bulletin al180 for Diazald and Diazomethane Generators). After distillation, the reaction was warmed to 25 °C and stirring was continued for 1 h. Glacial acetic acid was added dropwise after being chilled to quench excess diazomethane, and 33% HBr in acetic acid was added dropwise until a red tint persisted for more than 5 min. The solvent was removed in vacuo, and the products was re-dissolved in ethyl acetate and subsequently washed with water, sat. aq. NaHCO3 twice, and sat. aq. NaCl, and dried over MgSO<sub>4</sub>. A flame-dried 20 mL scintillation vial charged with anhydrous potassium fluoride (5 g, 100 mmol) and 26dimethylbenzoic acid (7.509 g. 50 mmol) in 10 mL of anhydrous dimethylformamide (DMF) was sonicated for 5 min. Compound 2 dissolved in a minimal amount of anhydrous DMF was added dropwise to stirred solution of carboxylic acid and base. After 30 min, the solution was diluted with 250 mL of ethyl acetate, washed twice with 200 mL of sat. aq. NaCl and briefly with 1 M NaOH, sat. aq. NaHCO3, and sat. aq. NaCl, and dried over MgSO4. The crude oil was purified by flash chromatography using 3:1 hexane/ethyl acetate to yield 3 in 81% yield.

For production of semicarbazide aminomethyl polystyrene resin (5), a flame-dried 500 mL round-bottom flask was charged with a magnetic stir bar, aminomethyl polystyrene resin (25 g, 28.75 mmol), and *N*,*N'*-carbonyldiimidazole (46.62 g, 287.5 mmol) in 250 mL of anhydrous dichloromethane (DCM), and the reaction was stirred under positive argon pressure for 3 h to generate 4 (Figure S5). The resin was washed once with anhydrous DCM and once with anhydrous DMF, transferred into a new flame-dried vessel, and resuspended in 250 mL of anhydrous DMF. To this stirred solution, anhydrous hydrazine (55.29 g, 54.15 mL, 1725 mmol) was added gradually over 5 min. The reaction was stirred at RT for 1 h. The resin was filtered, washed 5 times with DCM and 5 times with MeOH, dried thoroughly *in vacuo*, and stored at 4 °C.

A flame-dried 100 mL round-bottom flask was charged with amino acid 3 (1.09 g, 2.0 mmol) and 5 (1.00 g, 1.15 mmol/g), and the mixture was dried *in vacuo* for 6 h and suspended in 20 mL of anhydrous THF. This stirred solution was heated at 70 °C for 18 h to generate preloaded resin, Fmoc-Lys(Boc)–AOMK:SCR 6. The excess amino acid derivative was recovered, and the resin washed twice each with DMF, DCM, and MeOH, dried thoroughly, and stored at -20 °C.

For synthesis of Z-Arg-Lys–AOMK and Z-Glu-Lys–AOMK, preloaded resin 6 was presolvated in DCM for 30 min before two 15 min treatments of 5% diethylamine in DMF (1 mL/100 mg). Fmoc-glycine, *O*-(1*H*-6-chlorobenzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HCTU), and *N*,*N*-diisopropylethyl-

amine at a 3:3:10 ratio with respect to the loading of the resin were used to couple Z-Arg-OH or Z-Glu-OH. The resin was washed with DCM and MeOH 3 times before being dried *in vacuo*. Cleavage was performed using 1 mL of TFA/water/triisopropylsilane at a 95:2.5:2.5 ratio per 100 mg of resin for 1 h. The resin was washed with another aliquot of cleavage cocktail, and the combined cleavage solutions were concentrated before precipitation with cold diethyl ether. The pellet was dried under a stream of argon and dissolved in a minimal volume of DMSO before purification by preparatory reverse phase HPLC (19 mm × 150 mm XBridge C18, CH<sub>3</sub>CN/H<sub>2</sub>O/0.1% TFA, 25:75 to 70:30 over 13 min; 20 mL/min) and lyophilization.

Cathepsin B Activity Assayed by Fluorogenic Peptide Substrates. Proteolytic assays of cathepsin B were conducted with Z-Arg-Lys-AMC and Z-Gly-Lys-AMC substrates in 50 mM citrate phosphate at pH 7.2 or pH 4.6, 1 mM EDTA, 100 mM NaCl, and 5 mM DTT. Assays with Z-Phe-Arg-AMC substrate were conducted under identical conditions and included 0.01% Tween20. Assays were performed in 384 well plates at 25 °C in a total volume of 30  $\mu$ L. Fluorescence was quantified by a Biotek Synergy HTX microplate plate reader with excitation 360 nm, emission 460 nm, gain 50, top optics, and read height 1 mm. Proteolytic activity is reported as relative fluorescent units per second (RFU/s) and was calculated using the highest slope recorded for 10 consecutive readings. Fluorescent readings were taken in 46 s intervals, and therefore activity is calculated over a total of 460 s. To ensure that initial velocity is assessed, only readings within the first 30 min of the reaction were analyzed. RFU/s readings were converted to enzyme specific activity of  $pmol/(min/\mu g)$  using the conversion factor of 1227 RFU per micromolar AMC.

For Michaelis–Menten kinetic characterization, assays contained 20  $\mu$ L of substrate (Z-Phe-Arg–AMC, at different concentrations) and 10  $\mu$ L of 0.125 ng/ $\mu$ L cathepsin B for a final enzyme concentration of 0.0417 ng/ $\mu$ L. The final concentrations of substrates were 225  $\mu$ M to 2.6  $\mu$ M with DMSO concentration of 4.5% v/v.

For the substrates Z-Arg-Lys–AMC, Z-Glu-Lys–AMC, and Z-Phe-Arg–AMC,  $k_{cat}/K_m$  values were calculated using the equation  $v_0 = V_{max}[S]/(K_m + [S])$  where  $v_0$  is the activity at a corresponding substrate concentration [S] and  $V_{max}$  is the maximum enzyme velocity at saturated [S] concentration.  $V_{max} = k_{cat}[E]_T$ , where  $[E]_T$  is the total enzyme concentration.  $K_m$  is the x-axis value where  $y = V_{max}/2$  and  $V_{max}$  is the maximum rate at saturating substrate concentrations. At low [S],  $k_{cat}/K_m$  was calculated from the slope of the plot of  $v_0/[E]$  vs [S] concentration (linear portion of plot). All data was plotted, calculated, and analyzed using GraphPad Prism9 software.

To generate the pH profile of cathepsin B activity with the substrates Z-Arg-Lys-AMC, Z-Glu-Lys-AMC, and Z-Phe-Arg-AMC, 60  $\mu$ M of each substrate and 0.04 ng/ $\mu$ L cathepsin B were assayed in citrate phosphate buffers ranging from pH 2.2 to 7.4 in increments of 0.4 pH units, including pH 7.2. For assay buffers ranging from pH 7.4 to 9.0, 50 mM Tris-HCl was used instead of 50 mM citrate phosphate, with inclusion of pH 7.2.

Inhibitor Kinetic Characterization Using Fluorogenic Assays for Cathepsin B Activity. Kinetic analyses of  $IC_{50}$ ,  $K_{I}$ ,  $k_{obs}$ , and kinact/KI values for Z-Arg-Lys-AOMK and Z-Glu-Lys-AOMK inhibition of cathepsin B were conducted by fluorogenic proteolytic assays consisting of 40  $\mu$ M Z-Phe-Arg-AMC, 40 mM citrate phosphate at pH 7.2 or pH 4.6, 1 mM EDTA, 100 mM NaCl, 5 mM DTT, and 0.01% Tween 20; assays were performed at RT (22-27 °C) in quadruplicate. Inhibitor and substrate were combined in the reaction well, and the assay was started upon addition of cathepsin B (0.04 ng/ $\mu$ L). The inhibitor concentration ranged from 5.5  $\mu$ M to 1.1 nM (1.5-fold serial dilution). A vehicle control assay contained 2% DMSO instead of inhibitor. Enzyme velocity (RFU/s) was measured during a 30 min incubation period as relative fluorescent units per second (RFU/s), calculated using the highest slope recorded for 10 consecutive readings taken at 46 s intervals (thus, activity is calculated over a total of 460 s). Prism software was used to analyze enzyme activity data in kinetic studies. IC50 values were calculated (without preincubation of inhibitor and enzyme) as the concentration of inhibitor that reduced cathepsin B activity by 50%.

For determination of  $K_{\rm I}$  and  $k_{\rm inact}/K_{\rm I}$  kinetic inhibition constants,  $k_{\rm obs}$  constants were determined by plots of cathepsin B activity in time courses with different inhibitor concentrations by curve fitting slope data of RFU versus time into  $Y = Y_0 e^{(-k_{\rm obs}X)}$ , where  $Y_0$  is the activity for the control with no inhibitor condition, Y is the activity in the presence of inhibitor, and X is time.  $K_{\rm I}$  and  $k_{\rm inact}$  values were calculated from curve fitting the  $k_{\rm obs}$  values into the equation  $k_{\rm obs} = k_{\rm inact}[I]/(K_{\rm I} + [I])$ , where [I] is inhibitor concentration,  $K_{\rm I}$  is the x-axis inhibitor concentration at which  $y = k_{\rm inact}/2$ , and  $k_{\rm inact}$  is the maximum rate of inactivation at saturating inhibitor concentrations.<sup>92,93</sup> These kinetic analyses are for irreversible inhibitors, Z-Arg-Lys-AOMK and Z-Glu-Lys-AOMK of this study, that utilize  $K_{\rm I}$  values, rather than  $K_{\rm i}$  values used for reversible inhibitors.<sup>92</sup>

**Irreversible Mechanism of Inhibitors.** The irreversible or reversible mechanism of cathepsin B inhibition was assessed for Z-Arg-Lys–AOMK and Z-Glu-Lys–AOMK inhibitors. At pH 7.2, cathepsin B was incubated with 190 nM Z-Arg-Lys–AOMK and 4.99  $\mu$ M Z-Glu-Lys–AOMK for 15 min in pH 7.2 assay buffer, and the assay was performed as described above for pH 4.6. Proteolytic activity was monitored for 2 h. At pH 4.6, cathepsin B (activated, 3.7 ng/ $\mu$ L) was incubated with 4.24  $\mu$ M Z-Arg-Lys–AOMK and 3.48  $\mu$ M Z-Glu-Lys–AOMK for 15 min in 40 mM citrate phosphate (pH 4.6), 1 mM EDTA, 100 mM NaCl, and 5 mM DTT; a vehicle control contained 2.5% DMSO. Each reaction was then diluted 100-fold in assay buffer such that the final assay composition was 0.04 ng/ $\mu$ L cathepsin B, 40  $\mu$ M Z-Phe-Arg–AMC, and an inhibitor concentration of 1/10th the IC<sub>50</sub> value.

Inhibitor Inhibition of Peptide Cleavages Characterized by MSP-MS. MSP-MS assays in the presence of inhibitors were performed as outlined above except cathepsin B (0.1 ng/ $\mu$ L) was preincubated with Z-Arg-Lys–AOMK (64 nM) or a vehicle control (0.5% DMSO) for 30 min at 25 °C prior to incubation with the peptide library for 60 min in 40 mM citrate phosphate at pH 7.2 or pH 4.6, 1 mM EDTA, 100 mM NaCl, and 5 mM DTT buffer. Assays were conducted in quadruplicate and immediately stored at –70 °C following quenching with 8 M urea.

Specificity of Inhibitors for Other Cysteine Cathepsin Proteases. The effects of Z-Arg-Lys-AOMK and Z-Glu-Lys-AOMK on cathepsin V, L, K, S, X, H, and C activities were assessed. IC<sub>50</sub> values were calculated at pH 4.6 and pH 7.2 conditions, consisting of 40 mM citrate phosphate, 1 mM EDTA, 100 mM NaCl, and 5 mM DTT. The inhibitor concentrations ranged from 16.38  $\mu$ M to 0.5 nM with 2-fold serial dilutions. When activity (RFU/s) in the presence of 16.38  $\mu$ M inhibitor was reduced by <50% compared to DMSO control, the IC<sub>50</sub> value was indicated as >16  $\mu$ M. Cathepsin V (0.04 ng/ $\mu$ L), cathepsin L (0.03 ng/ $\mu$ L), cathepsin K (0.10 ng/ $\mu$ L), and cathepsin S (0.20 ng/ $\mu$ L) were assayed with 40  $\mu$ M Z-Phe-Arg-AMC. Cathepsin X (0.20 ng/ $\mu$ L), cathepsin C (0.51 ng/ $\mu$ L), and cathepsin H (0.1 ng/ $\mu$ L) were assayed with 40  $\mu$ M MCA-Arg-Pro-Pro-Gly-Phe-Ser-Ala-Phe-Lys(Dnp)OH, Gly-Arg-AMC, and Arg-AMC, respectively. Activation of pro-cathepsin H to cathepsin H was conducted by incubation of cathepsin H (4.4 ng/ $\mu$ L) with cathepsin L (1.1 ng/ $\mu$ L) at RT for 2 h in activation buffer (20 mM citrate phosphate (pH 6.0), 100 mM NaCl, and 5 mM DTT). Cathepsin C (13.78 ng/ $\mu$ L) was activated by incubation with cathepsin L (3.4 ng/  $\mu$ L) at RT for 1 h in activation buffer (20 mM citrate phosphate (pH 6.0), 100 mM NaCl, 5 mM DTT). It was confirmed that cathepsin L did not cleave the cathepsin C and cathepsin H substrates Gly-Arg-AMC and Arg-AMC, respectively. For all assays containing peptide-AMC substrates, the fluorescent microplate reader settings were the same as outlined above for cathepsin B. For the cathepsin X assay, the plate reader was set to excitation 320 nm, emission 400 nm, gain 105, top optics, and read height 1 mm. To convert RFU/s to pmol/min, 10  $\mu$ M to 0.005  $\mu$ M (2-fold serial dilution) of MCA-Arg-Pro-Pro-Gly-Phe-Ser-Ala-Phe-Lys(Dnp)OH was fully hydrolyzed with excess cathepsin X and a standard curve was generated using the total fluorescence values calculated at each concentration.

**MOE Modeling of Z-Arg-Lys–AOMK Binding Interactions with Cathepsin B.** The Molecular Operating Environment (MOE) modeling software<sup>64,65</sup> was used to model Z-Arg-Lys–AOMK binding to cathepsin B using the crystal structure of cathepsin B (PDB 1QDQ),<sup>60</sup> cocrystal template with the inhibitor CA-074 as default binding ligand. The builder function of MOE was used to examine binding poses that considered polar contacts and hydrogen bonds between ligand and the active site pocket of 1QDQ at pH 7.2. Docking simulations were performed with energy-minimized structures to assess ligand flexibility and poses using the MOE docking feature.

**Cathepsin B in Human Neuroblastoma Cells Treated with Inhibitors.** Neuroblastoma cells (human SHSY5Y) were grown in media consisting of 50% MEMalpha and 50% F12-K with 10% heatinactivated FBS at 37 °C in an atmosphere of 95% air and 5% CO<sub>2</sub>. First, cell homogenates were prepared by collection of cells in 0.32 M sucrose and freeze—thawing. Second, cells were incubated with Z-Arg-Lys—AOMK or CA-074Me for 6 h at 37 °C and washed 3 times in phosphate-buffered saline, and homogenates were prepared in 0.32 M sucrose with freeze—thawing. CA-074Me is a methyl ester form of the active CA-074 selective inhibitor of cathepsin  $B_i^{69}$  CA-074Me penetrates the cell and is converted by intracellular esterases to CA-074.

Cathepsin B activity in the homogenates was monitored with Z-Arg-Arg-AMC substrate (60  $\mu$ M) with buffer conditions of 40 mM citrate-phosphate (pH 5.5), 5 mM DTT, 1 mM EDTA, 100 mM NaCl, and 1.2% DMSO, followed by incubation at 37 °C for 30 min and reading of AMC fluorescence. CA-074-senstive activity was monitored to indicate cathepsin B activity, since CA-074 is a selective inhibitor of this enzyme.<sup>69</sup> Protein content was measured in homogenates with the DC protein assay kit. Cathepsin B specific activity was calculated as nmol AMC/( $\mu$ g/min) and reported as the mean  $\pm$  SD (with analyses for statistical significance, p < 0.05 by Student's *t* test).

#### ASSOCIATED CONTENT

#### **Supporting Information**

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acschembio.1c00138.

Cathepsin B cleavage locations of 14-mer peptide library substrates, MSP-MS analyses of cathepsin B cleavage properties at neutral and acidic pHs, inhibitor synthesis, kinetics of inhibition at neutral and acidic pH conditions, irreversible mechanism of inhibition, molecular docking of inhibitors to cathepsin B, and methods for the LC-MS/MS and PEAKs analyses of mass spectrometry data for MSP-MS (PDF) Workbook of MSP-MS data (XLSX)

AUTHOR INFORMATION

#### **Corresponding Authors**

- Anthony J. O'Donoghue Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California 92093, United States; Email: ajodonoghue@ucsd.edu
- Vivian Hook Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California 92093, United States; Department of Neurosciences, School of Medicine, University of California, San Diego, La Jolla, California 92037, United States;
  orcid.org/0000-0001-6461-7024; Email: vhook@ ucsd.edu

### Authors

Michael C. Yoon – Skaggs School of Pharmacy and Pharmaceutical Sciences and Biomedical Sciences Graduate Program, University of California, San Diego, La Jolla, California 92093, United States; orcid.org/0000-0002-2900-5257

- Angelo Solania Departments of Molecular Medicine and Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California 92037, United States; ◎ orcid.org/0000-0001-7872-4330
- Zhenze Jiang Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California 92093, United States; orcid.org/ 0000-0001-9570-1739
- Mitchell P. Christy Scripps Institution of Oceanography, University of California, San Diego, La Jolla, California 92093, United States
- Sonia Podvin Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California 92093, United States
- **Charles Mosier** Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California 92093, United States
- Christopher B. Lietz Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California 92093, United States
- **Gen Ito** Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California 92093, United States
- William H. Gerwick Scripps Institution of Oceanography, University of California, San Diego, La Jolla, California 92093, United States
- **Dennis W. Wolan** Departments of Molecular Medicine and Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California 92037, United States; © orcid.org/0000-0001-9879-8353
- **Gregory Hook** American Life Sciences Pharmaceuticals, Inc., La Jolla, California 92037, United States

Complete contact information is available at: https://pubs.acs.org/10.1021/acschembio.1c00138

## **Author Contributions**

V.H. and A.J.O. conceived the project idea and design. M.C.Y., A.S., S.P., and C.M. conducted the experiments. Z.J., S.P., and C.B.L. provided advice on mass spectrometry and bioinformatics analyses of data. A.S. and D.W. synthesized the AOMK peptidic inhibitors. M.P.C., M.C.Y., W.H.G., and V.H. conducted the MOE binding analyses. S.P. and C.M. performed the cellular studies. Literature evaluation was conducted by M.Y., G.I., A.J.O., G.H., and V.H. V.H., A.J.O., and M.Y. wrote the manuscript, with editing by V.H., A.J.O., M.C.Y., M.P.C., G.H., D.W.W., and W.H.G.

# Notes

The authors declare the following competing financial interest(s): V. Hook and G. Hook have equity positions at American Life Science Pharmaceuticals (ALSP), and are founders of ALSP; V. Hook is an advisor to ALSP. V. Hook's conflict has been disclosed and is managed by her employer, the University of California, San Diego. G. Hook at ALSP is vice-president of research, corporate counsel, and member of the board of directors. The other authors have no conflicts of interest.

LC-MS/MS files can be accessed at www.proteomexchange. org under the data set identifier numbers PXD022494 and PXD022493. Alternatively, the data files can be obtained through https://massive.ucsd.edu under the data set identifier numbers MSV000086449 and MSV000086447. Data analysis is provided in the Methods and Materials and the Supporting Information.

# ACKNOWLEDGMENTS

This research was supported by NIH Grant R01NS109075 (awarded to V.H.). M. Yoon was supported by NIH T32GM067550 (awarded to W. Gerwick).

#### REFERENCES

(1) De Duve, C.; Wattiaux, R. Functions of lysosomes. *Annu. Rev. Physiol.* **1966**, *28*, 435–92.

(2) Lawrence, R. E.; Zoncu, R. The lysosome as a cellular centre for signaling, metabolism and quality control. *Nat. Cell Biol.* **2019**, *21*, 133–142.

(3) Xu, H.; Ren, D. Lysosomal physiology. *Annu. Rev. Physiol.* 2015, 77, 57–80.

(4) Barrett, A. J.; Rawlings, N. D.; Woessner, J. F. Handbook of Proteolytic Enzymes, 2nd ed.; Elsevier Academic Press: Amsterdam, 2004.

(5) Turk, V.; Stoka, V.; Vasiljeva, O.; Renko, M.; Sun, T.; Turk, B.; Turk, D. Cysteine cathepsins: from structure, function and regulation to new frontiers. *Biochim. Biophys. Acta, Proteins Proteomics* **2012**, *1824*, 68–88.

(6) Mindell, J. A. Lysosomal acidification mechanisms. *Annu. Rev. Physiol.* **2012**, *74*, 69–86.

(7) Ishida, Y.; Nayak, S.; Mindell, J. A.; Grabe, M. A model of lysosomal pH regulation. J. Gen. Physiol. 2013, 141, 705-20.

(8) Ohkuma, S.; Poole, B. Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents. *Proc. Natl. Acad. Sci. U. S. A.* **1978**, *75*, 3327–31.

(9) Bright, G. R.; Fisher, G. W.; Rogowska, J.; Taylor, D. L. Fluorescence ratio imaging microscopy: temporal and spatial measurements of cytoplasmic pH. *J. Cell Biol.* **1987**, *104*, 1019–33.

(10) Madshus, I. H. Regulation of intracellular pH in eukaryotic cells. *Biochem. J.* **1988**, 250, 1–8.

(11) Swietach, P.; Tiffert, T.; Mauritz, J. M.; Seear, R.; Esposito, A.; Kaminski, C. F.; Lew, V. L.; Vaughan-Jones, R. D. Hydrogen ion dynamics in human red blood cells. *J. Physiol.* **2010**, *588*, 4995–5014. (12) Hook, V.; Yoon, M.; Mosier, C.; Ito, G.; Podvin, S.; Head, B. P.; Rissman, R.; O'Donoghue, A. J.; Hook, G. Cathepsin B in neurodegeneration of Alzheimer's disease, traumatic brain injury, and related brain disorders. *Biochim. Biophys. Acta, Proteins Proteomics* **2020**, *1868*, 140428.

(13) Nakanishi, H. Microglial cathepsin B as a key driver of inflammatory brain diseases and brain aging. *Neural Regener. Res.* **2020**, *15*, 25–29.

(14) Yang, A. J.; Chandswangbhuvana, D.; Margol, L.; Glabe, C. G. Loss of endosomal/lysosomal membrane impermeability is an early event in amyloid Abeta1–42 pathogenesis. *J. Neurosci. Res.* **1998**, *52*, 691–8.

(15) Ditaranto, K.; Tekirian, T. L.; Yang, A. J. Lysosomal membrane damage in soluble Abeta-mediated cell death in Alzheimer's disease. *Neurobiol. Dis.* **2001**, *8*, 19–31.

(16) De Kimpe, L.; van Haastert, E. S.; Kaminari, A.; Zwart, R.; Rutjes, H.; Hoozemans, J. J.; Scheper, W. Intracellular accumulation of aggregated pyroglutamate amyloid beta: convergence of aging and  $A\beta$  pathology at the lysosome. *Age* **2013**, *35*, 673–87.

(17) Umeda, T.; Tomiyama, T.; Sakama, N.; Tanaka, S.; Lambert, M. P.; Klein, W. L.; Mori, H. Intraneuronal amyloid  $\beta$  oligomers cause cell death via endoplasmic reticulum stress, endosomal/lysosomal leakage, and mitochondrial dysfunction in vivo. *J. Neurosci. Res.* **2011**, *89*, 1031–42.

(18) Lafrenaye, A. D.; McGinn, M. J.; Povlishock, J. T. Increased intracranial pressure after diffuse traumatic brain injury exacerbates neuronal somatic membrane poration but not axonal injury: evidence for primary intracranial pressure-induced neuronal perturbation. *J. Cereb. Blood Flow Metab.* **2012**, *32*, 1919–32.

(19) Luo, C. L.; Chen, X. P.; Li, L. L.; Li, Q. Q.; Li, B. X.; Xue, A. M.; Xu, H. F.; Dai, D. K.; Shen, Y. W.; Tao, L. Y.; Zhao, Z. Q. Poloxamer 188 attenuates in vitro traumatic brain injury-induced mitochondrial and lysosomal membrane permeabilization damage in cultured primary neurons. *J. Neurotrauma* **2013**, *30*, 597–607.

(20) Windelborn, J. A.; Lipton, P. Lysosomal release of cathepsins causes ischemic damage in the rat hippocampal slice and depends on NMDA-mediated calcium influx, arachidonic acid metabolism, and free radical production. *J. Neurochem.* **2008**, *106*, 56–69.

(21) Kilinc, M.; Gürsoy-Ozdemir, Y.; Gürer, G.; Erdener, S. E.; Erdemli, E.; Can, A.; Dalkara, T. Lysosomal rupture, necroapoptotic interactions and potential crosstalk between cysteine proteases in neurons shortly after focal ischemia. *Neurobiol. Dis.* **2010**, *40*, 293–302.

(22) Dong, H.; Qin, Y.; Huang, Y.; Ji, D.; Wu, F. Poloxamer 188 rescues MPTP-induced lysosomal membrane integrity impairment in cellular and mouse models of Parkinson's disease. *Neurochem. Int.* **2019**, *126*, 178–186.

(23) Freeman, D.; Cedillos, R.; Choyke, S.; Lukic, Z.; McGuire, K.; Marvin, S.; Burrage, A. M.; Sudholt, S.; Rana, A.; O'Connor, C.; Wiethoff, C. M.; Campbell, E. M. Alpha-synuclein induces lysosomal rupture and cathepsin dependent reactive oxygen species following endocytosis. *PLoS One* **2013**, *8*, e62143.

(24) Amritraj, A.; Peake, K.; Kodam, A.; Salio, C.; Merighi, A.; Vance, J. E.; Kar, S. Increased activity and altered subcellular distribution of lysosomal enzymes determine neuronal vulnerability in Niemann-Pick type C1-deficient mice. *Am. J. Pathol.* **2009**, *175*, 2540–56.

(25) Chung, C.; Puthanveetil, P.; Ory, D. S.; Lieberman, A. P. Genetic and pharmacological evidence implicates cathepsins in Niemann-Pick C cerebellar degeneration. *Hum. Mol. Genet.* **2016**, *25*, 1434–46.

(26) Fujisawa, A.; Kambe, N.; Saito, M.; Nishikomori, R.; Tanizaki, H.; Kanazawa, N.; Adachi, S.; Heike, T.; Sagara, J.; Suda, T.; Nakahata, T.; Miyachi, Y. Disease-associated mutations in CIAS1 induce cathepsin B-dependent rapid cell death of human THP-1 monocytic cells. *Blood* **2007**, *109*, 2903–11.

(27) Fujisawa, A.; Kambe, N.; Saito, M.; Nishikomori, R.; Tanizaki, H.; Kanazawa, N.; Adachi, S.; Heike, T.; Sagara, J.; Suda, T.; Nakahata, T.; Miyachi, Y. Disease-associated mutations in CIAS1 induce cathepsin B-dependent rapid cell death of human THP-1 monocytic cells. *Blood* **2007**, *109*, 2903–11.

(28) Rajamäki, K.; Lappalainen, J.; Oörni, K.; Välimäki, E.; Matikainen, S.; Kovanen, P. T.; Eklund, K. K. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. *PLoS One* **2010**, *5*, e11765.

(29) Gonzalez, E. A.; Martins, G. R.; Tavares, A. M. V.; Viegas, M.; Poletto, E.; Giugliani, R.; Matte, U.; Baldo, G. Cathepsin B inhibition attenuates cardiovascular pathology in mucopolysaccharidosis I mice. *Life Sci.* **2018**, *196*, 102–109.

(30) Saluja, A.; Dudeja, V.; Dawra, R.; Sah, R. P. Early Intra-Acinar Events in Pathogenesis of Pancreatitis. *Gastroenterology* **2019**, *156*, 1979–1993.

(31) Amaral, E. P.; Riteau, N.; Moayeri, M.; Maier, N.; Mayer-Barber, K. D.; Pereira, R. M.; Lage, S. L.; Kubler, A.; Bishai, W. R.; D'Império-Lima, M. R.; Sher, A.; Andrade, B. B. Lysosomal Cathepsin Release Is Required for NLRP3-Inflammasome Activation by *Mycobacterium tuberculosis* in Infected Macrophages. *Front. Immunol.* **2018**, *9*, 1427.

(32) Morchang, A.; Panaampon, J.; Suttitheptumrong, A.; Yasamut, U.; Noisakran, S.; Yenchitsomanus, P. T.; Limjindaporn, T. Role of cathepsin B in dengue virus-mediated apoptosis. *Biochem. Biophys. Res. Commun.* **2013**, 438, 20–5.

(33) de Castro, M. A.; Bunt, G.; Wouters, F. S. Cathepsin B launches an apoptotic exit effort upon cell death-associated disruption of lysosomes. *Cell Death Discov* **2016**, *2*, 16012.

(34) Droga-Mazovec, G.; Bojic, L.; Petelin, A.; Ivanova, S.; Romih, R.; Repnik, U.; Salvesen, G. S.; Stoka, V.; Turk, V.; Turk, B. Cysteine

cathepsins trigger caspase-dependent cell death through cleavage of bid and antiapoptotic Bcl-2 homologues. *J. Biol. Chem.* **2008**, 283, 19140–50.

(35) Kavčič, N.; Pegan, K.; Turk, B. Lysosomes in programmed cell death pathways: from initiators to amplifiers. *Biol. Chem.* **2017**, *398*, 289–301.

(36) Wei, M. C.; Lindsten, T.; Mootha, V. K.; Weiler, S.; Gross, A.; Ashiya, M.; Thompson, C. B.; Korsmeyer, S. J. tBID, a membranetargeted death ligand, oligomerizes BAK to release cytochrome c. *Genes Dev.* **2000**, *14*, 2060–71.

(37) Campden, R. I.; Zhang, Y. The role of lysosomal cysteine cathepsins in NLRP3 inflammasome activation. *Arch. Biochem. Biophys.* **2019**, 670, 32–42.

(38) Bai, H.; Yang, B.; Yu, W.; Xiao, Y.; Yu, D.; Zhang, Q. Cathepsin B links oxidative stress to the activation of NLRP3 inflammasome. *Exp. Cell Res.* **2018**, *362*, 180–187.

(39) Lian, D.; Lai, J.; Wu, Y.; Wang, L.; Chen, Y.; Zhang, Y.; Boini, K. M.; Huang, Y.; Chen, Y. Cathepsin B-mediated NLRP3 inflammasome formation and activation in angiotensin II -Induced hypertensive mice: role of macrophage digestion dysfunction. *Cell. Physiol. Biochem.* **2018**, *50*, 1585–1600.

(40) Kindy, M. S.; Yu, J.; Zhu, H.; El-Amouri, S. S.; Hook, V.; Hook, G. R. Deletion of the cathepsin B gene improves memory deficits in a transgenic Alzheimer's disease mouse model expressing  $A\beta$ PP containing the wild-type  $\beta$ -secretase site sequence. J. Alzheimer's Dis. **2012**, 29, 827–40.

(41) Hook, G. R.; Yu, J.; Sipes, N.; Pierschbacher, M. D.; Hook, V.; Kindy, M. S. The cysteine protease cathepsin B is a key drug target and cysteine protease inhibitors are potential therapeutics for traumatic brain injury. *J. Neurotrauma* **2014**, *31*, 515–29.

(42) Buck, M. R.; Karustis, D. G.; Day, N. A.; Honn, K. V.; Sloane, B. F. Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumour tissues. *Biochem. J.* **1992**, *282*, 273–8.

(43) Cavallo-Medved, D.; Dosescu, J.; Linebaugh, B. E.; Sameni, M.; Rudy, D.; Sloane, B. F. Mutant K-ras regulates cathepsin B localization on the surface of human colorectal carcinoma cells. *Neoplasia* **2003**, *5*, 507–19.

(44) Victor, B. C.; Anbalagan, A.; Mohamed, M. M.; Sloane, B. F.; Cavallo-Medved, D. Inhibition of cathepsin B activity attenuates extracellular matrix degradation and inflammatory breast cancer invasion. *Breast Cancer Res.* **2011**, *13*, R115.

(45) Aggarwal, N.; Sloane, B. F. Cathepsin B: multiple roles in cancer. *Proteomics: Clin. Appl.* **2014**, *8*, 427–37.

(46) Bian, B.; Mongrain, S.; Cagnol, S.; Langlois, M. J.; Boulanger, J.; Bernatchez, G.; Carrier, J. C.; Boudreau, F.; Rivard, N. Cathepsin B promotes colorectal tumorigenesis, cell invasion, and metastasis. *Mol. Carcinog.* **2016**, *55*, 671–87.

(47) Mort, J. S.; Recklies, A. D.; Poole, A. R. Extracellular presence of the lysosomal proteinase cathepsin B in rheumatoid synovium and its activity at neutral pH. *Arthritis Rheum.* **1984**, *27*, 509–15.

(48) Jordans, S.; Jenko-Kokalj, S.; Kühl, N. M.; Tedelind, S.; Sendt, W.; Brömme, D.; Turk, D.; Brix, K. Monitoring compartment-specific substrate cleavage by cathepsins B, K, L, and S at physiological pH and redox conditions. *BMC Biochem* **2009**, *10*, 23.

(49) Tedelind, S.; Poliakova, K.; Valeta, A.; Hunegnaw, R.; Yemanaberhan, E. L.; Heldin, N. E.; Kurebayashi, J.; Weber, E.; Kopitar-Jerala, N.; Turk, B.; Bogyo, M.; Brix, K. Nuclear cysteine cathepsin variants in thyroid carcinoma cells. *Biol. Chem.* **2010**, *391*, 923–35.

(50) Hämälistö, S.; Stahl, J. L.; Favaro, E.; Yang, Q.; Liu, B.; Christoffersen, L.; Loos, B.; Guasch Boldú, C.; Joyce, J. A.; Reinheckel, T.; Barisic, M.; Jäättelä, M. Spatially and temporally defined lysosomal leakage facilitates mitotic chromosome segregation. *Nat. Commun.* **2020**, *11*, 229.

(51) Almeida, P. C.; Nantes, I. L.; Chagas, J. R.; Rizzi, C. C.; Faljoni-Alario, A.; Carmona, E.; Juliano, L.; Nader, H. B.; Tersariol, I. L. Cathepsin B activity regulation. Heparin-like glycosaminogylcans protect human cathepsin B from alkaline pH-induced inactivation. *J. Biol. Chem.* **2001**, 276, 944–51. (52) Pratt, M. R.; Sekedat, M. D.; Chiang, K. P.; Muir, T. W. Direct measurement of cathepsin B activity in the cytosol of apoptotic cells by an activity-based probe. *Chem. Biol.* **2009**, *16*, 1001–12.

(53) O'Donoghue, A. J.; Eroy-Reveles, A. A.; Knudsen, G. M.; Ingram, J.; Zhou, M.; Statnekov, J. B.; Greninger, A. L.; Hostetter, D. R.; Qu, G.; Maltby, D. A.; Anderson, M. O.; Derisi, J. L.; McKerrow, J. H.; Burlingame, A. L.; Craik, C. S. Global identification of peptidase specificity by multiplex substrate profiling. *Nat. Methods* **2012**, *9*, 1095–100.

(54) Lapek, J. D., Jr; Jiang, Z.; Wozniak, J. M.; Arutyunova, E.; Wang, S. C.; Lemieux, M. J.; Gonzalez, D. J.; O'Donoghue, A. J. Quantitative Multiplex Substrate Profiling of Peptidases by Mass Spectrometry. *Mol. Cell Proteomics* **2019**, *18*, 968–981.

(55) Ivry, S. L.; Knudsen, G. M.; Caiazza, F.; Sharib, J. M.; Jaradeh, K.; Ravalin, M.; O'Donoghue, A. J.; Kirkwood, K. S.; Craik, C. S. The lysosomal aminopeptidase tripeptidyl peptidase 1 displays increased activity in malignant pancreatic cysts. *Biol. Chem.* **2019**, *400*, 1629–1638.

(56) Xu, J. H.; Jiang, Z.; Solania, A.; Chatterjee, S.; Suzuki, B.; Lietz, C. B.; Hook, V. Y. H.; O'Donoghue, A. J.; Wolan, D. W. A Commensal Dipeptidyl Aminopeptidase with Specificity for N-Terminal Glycine Degrades Human-Produced Antimicrobial Peptides in Vitro. *ACS Chem. Biol.* **2018**, *13*, 2513–2521.

(57) Leontovyč, A.; Ulrychová, L.; O'Donoghue, A. J.; Vondrášek, J.; Marešová, L.; Hubálek, M.; Fajtová, P.; Chanová, M.; Jiang, Z.; Craik, C. S.; Caffrey, C. R.; Mareš, M.; Dvořák, J.; Horn, M. SmSP2: A serine protease secreted by the blood fluke pathogen Schistosoma mansoni with anti-hemostatic properties. *PLoS Neglected Trop. Dis.* **2018**, *12*, e0006446.

(58) Li, H.; Goh, B. N.; Teh, W. K.; Jiang, Z.; Goh, J. P. Z.; Goh, A.; Wu, G.; Hoon, S. S.; Raida, M.; Camattari, A.; Yang, L.; O'Donoghue, A. J.; Dawson, T. L., Jr. Skin Commensal Malassezia globosa Secreted Protease Attenuates Staphylococcus aureus Biofilm Formation. *J. Invest. Dermatol.* **2018**, *138*, 1137–1145.

(59) Beekman, C.; Jiang, Z.; Suzuki, B. M.; Palmer, J. M.; Lindner, D. L.; O'Donoghue, A. J.; Knudsen, G. M.; Bennett, R. J. Characterization of PdCP1, a serine carboxypeptidase from Pseudogymnoascus destructans, the causal agent of White-nose Syndrome. *Biol. Chem.* **2018**, *399*, 1375–1388.

(60) Yamamoto, A.; Tomoo, K.; Hara, T.; Murata, M.; Kitamura, K.; Ishida, T. Substrate specificity of bovine cathepsin B and its inhibition by CA074, based on crystal structure refinement of the complex. *J. Biochem.* **2000**, *127*, 635–43.

(61) Thornberry, N. A.; Peterson, E. P.; Zhao, J. J.; Howard, A. D.; Griffin, P. R.; Chapman, K. T. Inactivation of interleukin-1 beta converting enzyme by peptide (acyloxy)methyl ketones. *Biochemistry* **1994**, *33*, 3934–40.

(62) Albrow, V. E.; Ponder, E. L.; Fasci, D.; Békés, M.; Deu, E.; Salvesen, G. S.; Bogyo, M. Development of small molecule inhibitors and probes of human SUMO deconjugating proteases. *Chem. Biol.* **2011**, *18*, 722–32.

(63) Shan, L. Carbobenzoxy-capped Phe-Lys(Cy5)-acyloxymethyl ketone. *Molecular Imaging and Contrast Agent Database (MICAD)* [*Internet*]. National Center for Biotechnology Information (US): Bethesda, MD, 2010 May 9 [updated 2010 May 25].

(64) Vilar, S.; Cozza, G.; Moro, S. Medicinal chemistry and the molecular operating environment (MOE): application of QSAR and molecular docking to drug discovery. *Curr. Top. Med. Chem.* **2008**, *8*, 1555–72.

(65) Roy, U.; Luck, L. A. Molecular modeling of estrogen receptor using molecular operating environment. *Biochem. Mol. Biol. Educ.* **2007**, *35*, 238–43.

(66) Schechter, I. Mapping of the active site of proteases in the 1960s and rational design of inhibitors/drugs in the 1990s. *Curr. Protein Pept. Sci.* 2005, *6*, 501–12.

(67) Hasnain, S.; Hirama, T.; Huber, C. P.; Mason, P.; Mort, J. S. Characterization of cathepsin B specificity by site-directed mutagenesis. Importance of Glu245 in the S2-P2 specificity for arginine and its role in transition state stabilization. J. Biol. Chem. 1993, 268, 235-40.

(68) Musil, D.; Zucic, D.; Turk, D.; Engh, R. A.; Mayr, I.; Huber, R.; Popovic, T.; Turk, V.; Towatari, T.; Katunuma, N. The refined 2.15 A X-ray crystal structure of human liver cathepsin B: the structural basis for its specificity. *EMBO J.* **1991**, *10*, 2321–30.

(69) Murata, M.; Miyashita, S.; Yokoo, C.; Tamai, M.; Hanada, K.; Hatayama, K.; Towatari, T.; Nikawa, T.; Katunuma, N. Novel epoxysuccinyl peptides. Selective inhibitors of cathepsin B, in vitro. *FEBS Lett.* **1991**, *280*, 307–10.

(70) Buttle, D. J.; Murata, M.; Knight, C. G.; Barrett, A. J. CA074 methyl ester: a proinhibitor for intracellular cathepsin B. Arch. Biochem. Biophys. **1992**, 299, 377–80.

(71) Choe, Y.; Leonetti, F.; Greenbaum, D. C.; Lecaille, F.; Bogyo, M.; Brömme, D.; Ellman, J. A.; Craik, C. S. Substrate profiling of cysteine proteases using a combinatorial peptide library identifies functionally unique specificities. *J. Biol. Chem.* **2006**, *281*, 12824–32. (72) Poreba, M.; Groborz, K.; Vizovisek, M.; Maruggi, M.; Turk, D.;

Turk, B.; Powis, G.; Drag, M.; Salvesen, G. S. Fluorescent probes towards selective cathepsin B detection and visualization in cancer cells and patient samples. *Chem. Sci.* **2019**, *10*, 8461–8477.

(73) Turk, B.; Dolenc, I.; Zerovnik, E.; Turk, D.; Gubensek, F.; Turk, V. Human cathepsin B is a metastable enzyme stabilized by specific ionic interactions associated with the active site. *Biochemistry* **1994**, 33, 14800–6.

(74) Song, J.; Xu, P.; Xiang, H.; Su, Z.; Storer, A. C.; Ni, F. The active-site residue Cys-29 is responsible for the neutral-pH inactivation and the refolding barrier of human cathepsin B. *FEBS Lett.* **2000**, 475, 157–62.

(75) Vidak, E.; Javoršek, U.; Vizovišek, M.; Turk, B. Cysteine Cathepsins and their Extracellular Roles: Shaping the Microenvironment. *Cells* **2019**, *8*, 264.

(76) Spizz, G.; Blackshear, P. J. Identification and characterization of cathepsin B as the cellular MARCKS cleaving enzyme. *J. Biol. Chem.* **1997**, *272*, 23833–42.

(77) Maciewicz, R. A.; Wotton, S. F.; Etherington, D. J.; Duance, V. C. Susceptibility of the cartilage collagens types II, IX and XI to degradation by the cysteine proteinases, cathepsins B and L. *FEBS Lett.* **1990**, *269*, 189–93.

(78) Taha, T. A.; Kitatani, K.; Bielawski, J.; Cho, W.; Hannun, Y. A.; Obeid, L. M. Tumor necrosis factor induces the loss of sphingosine kinase-1 by a cathepsin B-dependent mechanism. *J. Biol. Chem.* **2005**, 280, 17196–202.

(79) Illy, C.; Quraishi, O.; Wang, J.; Purisima, E.; Vernet, T.; Mort, J. S. Role of the occluding loop in cathepsin B activity. *J. Biol. Chem.* **1997**, 272, 1197–202.

(80) Nägler, D. K.; Storer, A. C.; Portaro, F. C.; Carmona, E.; Juliano, L.; Ménard, R. Major increase in endopeptidase activity of human cathepsin B upon removal of occluding loop contacts. *Biochemistry* **1997**, *36*, 12608–15.

(81) Melo, R. L.; Barbosa Pozzo, R. C.; Alves, L. C.; Perissutti, E.; Caliendo, G.; Santagada, V.; Juliano, L.; Juliano, M. A. Synthesis and hydrolysis by cathepsin B of fluorogenic substrates with the general structure benzoyl-X-ARG-MCA containing non-natural basic amino acids at position X. *Biochim. Biophys. Acta, Protein Struct. Mol. Enzymol.* **2001**, *1547*, 82–94.

(82) Linebaugh, B. E.; Sameni, M.; Day, N. A.; Sloane, B. F.; Keppler, D. Exocytosis of active cathepsin B enzyme activity at pH 7.0, inhibition and molecular mass. *Eur. J. Biochem.* **1999**, *264*, 100–9.

(83) Boutté, A. M.; Hook, V.; Thangavelu, B.; Sarkis, G. A.; Abbatiello, B. N.; Hook, G.; Jacobsen, J. S.; Robertson, C. S.; Gilsdorf, J.; Yang, Z.; Wang, K. K. W.; Shear, D. A. Penetrating Traumatic Brain Injury Triggers Dysregulation of Cathepsin B Protein Levels Independent of Cysteine Protease Activity in Brain and Cerebral Spinal Fluid. J. Neurotrauma 2020, 37, 1574–1586.

(84) Hoegen, T.; Tremel, N.; Klein, M.; Angele, B.; Wagner, H.; Kirschning, C.; Pfister, H. W.; Fontana, A.; Hammerschmidt, S.; Koedel, U. The NLRP3 inflammasome contributes to brain injury in (85) Yamashima, T. Can 'calpain-cathepsin hypothesis' explain Alzheimer neuronal death? *Ageing Res. Rev.* **2016**, *32*, 169–179.

(86) Yamashima, T. Hsp70.1 and related lysosomal factors for necrotic neuronal death. J. Neurochem. 2012, 120, 477–94.

(87) Zhang, X.; Lin, Y.; Gillies, R. J. Tumor pH and its measurement. J. Nucl. Med. 2010, 51, 1167-70.

(88) Chen, L. Q.; Pagel, M. D. Evaluating pH in the Extracellular Tumor Microenvironment Using CEST MRI and Other Imaging Methods. *Adv. Radiol* 2015, 2015, 206405.

(89) O'Donoghue, A. J.; Knudsen, G. M.; Beekman, C.; Perry, J. A.; Johnson, A. D.; DeRisi, J. L.; Craik, C. S.; Bennett, R. J. Destructin-1 is a collagen-degrading endopeptidase secreted by Pseudogymnoascus destructans, the causative agent of white-nose syndrome. *Proc. Natl. Acad. Sci. U. S. A.* **2015**, *112*, 7478–83.

(90) Rorabacher, D. B. Statistical treatment for rejection of deviant values: critical values of Dixon's Q parameter and related subrange ratios at the 95% confidence level. *Anal. Chem.* **1991**, *63*, 139–146.

(91) Colaert, N.; Helsens, K.; Martens, L.; Vandekerckhove, J.; Gevaert, K. Improved visualization of protein consensus sequences by iceLogo. *Nat. Methods* **2009**, *6*, 786–787.

(92) Strelow, J. M. A Perspective on the Kinetics of Covalent and Irreversible Inhibition. *SLAS Discov* **2017**, *22*, 3–20.

(93) Tonge, P. J. Quantifying the Interactions between Biomolecules: Guidelines for Assay Design and Data Analysis. *ACS Infect. Dis.* **2019**, *5*, 796–808.